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ABSTRACT 
EXPLOITATION OF COSTIMULATORY SA-4-1BBL IN THE DEVELOPMENT OF 
THERAPEUTIC CANCER VACCINES 
Abhishek K. Srivastava 
March 31, 2011 
Cancer accounts for nearly one-quarter of deaths in the United States, exceeded 
only by heart diseases. Despite the development of various strategies to treat cancer, it 
remains one of the most deadly diseases worldwide due to the limited effects of 
treatments available. The limited efficacy of these current treatment modalities, such as 
surgery, radiotherapy, and chemotherapy, are often due to their association with adverse 
side effects arising from lack of specificity for tumors, and most importantly their failure 
of eliminating residual and micro-metastatic tumors, which can lead to recurrences. 
Therefore, there is a dire need to develop tumor-specific therapies that not only eliminate 
primary tumors, but also micro-metastasis and prevent recurrences. In this regard, 
therapeutic cancer vaccines based on tumor-associated antigens (TAAs) has evolved as a 
promising approach due to their safety profile, ease of production, storage, transportation, 
administration to a broad patient population and most importantly establishment and/or 
maintenance of long-term immunological memory critical for the control of recurrences, 
a major cause of cancer death. However, despite theoretical promise, development of 
therapeutic cancer vaccines has been facing numerous set-backs mostly due to the weak 
immunogenicity of T AAs, tolerance to self-T AAs and various immune evasion 
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mechanisms employed by progressing tumors. Therefore, we hypothesized that use of 
natural costimulatory ligands of TNF family as adjuvant may overcome these limitations 
due to their effect on cells of innate, adaptive, and regulatory immunity without any sign 
of toxicity. The tumor necrosis factor receptor (TNFR)/TNF superfamily represents a 
crucial group of costimulatory receptor/ligands as most of the receptors of this family are 
inducibly expressed on various immune cells. Costimulatory receptors that are inducibly 
expressed or upregulated on activated T cells may serve as preferred targets for 
immunomodulation due to their potential to selectively target antigen-experienced T cells 
for expansion, survival, and establishment oflong-term immunological memory. Among 
these family members, 4-1BB/4-1BBL signaling has recently been much appreciated as 
its signaling provides the essential survival signals, particularly in CD8+ T cells. 4-1BB 
signaling into T cells allows CD8+ T cell expansion, cytokine production, development of 
CTL effector function, and prevention of apoptotic cell death by up-regulating anti-
apoptotic Bcl-xL and Bcl-2 molecules. As the aim of tumor immunotherapy is to generate 
long-lasting immune response, particularly CD8+ T cell specific response, for the 
destruction of tumor cells, in this project, we focused on the utilization of 4-1 BBL either 
alone or in combination with other immunomodulators, as a component of TAA-based 
subunit vaccines and tested its efficacy in preclinical mice tumor models. 
First, we report that a single immunization with a therapeutic vaccine formulation 
containing novel form of soluble SA-4-1BBL, and survivin (SVN), a bona fide self 
antigen, resulted into the eradication of SVN-expressing 3LL tumors in 75% of mice in 
the absence of autoimmunity. The efficacy of vaccine was further improved to complete 
tumor eradication with an additional vaccination 6 days after the first vaccination. CD8+ 
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T cells and NK cells effector function was found to be critical for the efficacy of vaccine, 
but not the CD4 + T cells. 
Next, we tested the vaccine formulation containing combination of SA-4-IBBL 
and toll-like receptor 4 agonist monophosphoryllipid A (MPL) with distinct mechanisms 
of action as a novel adjuvant system. A single immunization with both adjuvants and 
HPV E7 protein resulted in eradication of 100% of E7 expressing TC-I tumors. 
Combined adjuvants had better therapeutic efficacy over the individual adjuvants, while 
SA-4-IBBL monotherapy outperformed MPL, 80% vs. 50%. Similarly, a single 
vaccination with SVN resulted in control/eradication of established 3LL pulmonary 
metastases that was further improved by a booster injection. The therapeutic efficacy of 
combined adjuvants as well as SA-4-IBBL as monotherapy was achieved in the absence 
of detectable toxicity and correlated with enhanced CD8+ T cell function and increased 
intratumoral CD8+ T effector/CD4+FoxP3+ T regulatory cell ratio. In marked contrast, 
vaccination with MPL as monotherapy resulted in an unfavorable intratumoral CD8+ T 
effector/CD4+FoxP3+ T regulatory cell ratio that played a definitive role in vaccine 
efficacy. Depletion of T regulatory cells improved MPL efficacy to 100%, whereas 
elimination of CD8+ T cells totally abrogated the efficacy of combined adjuvants. 
In last, we report that combination of SA-4-IBBL and SA-OX40L, another 
member of TNF ligand family, was also able to eradicate TC-I tumors in 100% of mice. 
This efficacy was mainly dependent on CD8+ T cells as depletion of these cells 
completely abrogated the efficacy. Importantly, combination of these two ligands was 
also able to eradicate a 3-4 mm established tumors in 50% of mice. 
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Taken together, these data provide important mechanistic insight into the mode of 
action of SA-4-1BBL alone or in combination either MPL or SA-OX40L adjuvants and 
demonstrate its utility as a novel adjuvant system for the development of therapeutic 
TAA-based subunit cancer vaccines with significant clinical implications. These data also 
shed lights into the mode of action of MPL and SA-OX40L as a part of vaccine adjuvant 
systems and set the stage for their utilization in the development of new vaccine 
strategies. 
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Cancer is the one of the leading causes of death in the United States and 
worldwide. Despite growing efforts in the development of various strategies to treat 
cancer, it remains one of the most deadly diseases with the limited effects of treatments 
available. The limited efficacy of these current treatment modalities, such as surgery, 
radiotherapy, and chemotherapy, are often due to their association with adverse side 
effects arising from lack of specificity for tumors, and most importantly their failure of 
eliminating residual and micro-metastatic tumors, which can lead to recurrences (1). 
Therefore, there is a dire need to develop tumor-specific therapies that not only eliminate 
primary tumors, but also micro-metastasis and prevent recurrences. In this scenario, 
therapeutic cancer vaccines based on tumor associated antigens (TAAs) are preferred 
alternatives to conventional treatments primarily because of their safety profile and 
generation of long-term immunological memory critical for the control of recurrences, 
which are major cause of death from cancer. 
The theory of cancer immune-surveillance suggests that the immune system has 
the ability to recognize precursors of cancer and, in most cases, mount an effective 
response to destroy these precursors before they become clinically apparent (2). This 
notion is supported by observations that mice lacking essential components of the innate 
or adaptive immune responses are susceptible to the development of spontaneous or 
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designed to enhance the ability of immune system can reduce the development of 
malignant disease in animal models. If immune-surveillance plays a key role In 
controlling the tumor progreSSIOn, then one would expect the patients with pre-
malignancy will mount vigorous immune responses. There are, indeed, scientific 
evidences indicating that this might be the case. Patients with monoclonal gammopathy, a 
pre-malignant disease, mount strong T cell responses against autologous pre-malignant B 
cells, whereas no responses are found in patients with malignant multiple myeloma (3). 
Additionally, breast cancer-associated proteins mucin-l and HER2 specific CD8+ T cells 
from breast cancer patients are able to regress autologous human tumors that have been 
transplanted into immunodeficient non-obese diabetic mice (4). These studies suggest 
that, although tumors induce at least transient immune responses, cancer can still 
develop. This indicate that such cellular immune responses are either too low to prevent 
the tumor progression or evaded by tumor cells as its safety mechanism. Therefore, the 
development of therapeutic cancer vaccines capable of generating a robust tumor-specific 
immunity may serve as a promising tool for cancer treatment. However, despite 
demonstrated efficacy in test tubes and experimental animals, efforts to harness the 
immune system to fight cancer using cancer vaccines have been challenging for decades 
and have largely ended in failure. This may be due to the weak antigenic nature of self 
tumor-associated antigens (TAAs), both central and peripheral tolerogenic mechanisms, 
and various immune evasion mechanisms employed by the progressing tumors. These 
limitations can potentially be overcome by developing vaccine formulations including 
adjuvants that not only generate potent immune responses against T AAs with long-term 
immunological memory, but also overcome various immune evasion mechanisms. 
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Cancer Vaccines: 
The development of successful vaccines against infectious diseases is one of 
medicine's most important accomplishments. Their influence on majority of human 
population is aptly expressed by vaccinologist Stanley Plotkin when he says: "The impact 
of vaccination on human health of the world's peoples is hard to exaggerate. With the 
exception of safe water, no other modality, not even antibiotics, has had such a major 
effect on mortality reduction and population growth" (5). The success of these vaccines 
primarily lies in their ability to induce long-lived antibody responses that protect against 
highly immunogenic bacteria and viruses. However, development of therapeutic vaccines 
against cancer faces a much greater challenges because their target often consist of 
tumor-associated self-antigens (TAAs), which are poorly immunogenic and often 
heterogeneously expressed by genetically unstable tumor cells that undergo mutations 
and frequently suppress immune responses at the cellular level in the tumor 
microenvironment. Therefore, despite several encouraging advances in the area of 
vaccinology, cancer is still a major public health problem worldwide, and requires new 
strategies for the development of potent vaccines to optimize patient outcomes. 
In the last several years, numerous strategies such as cell-based vaccines, DNA-
or RNA-based vaccines, protein/peptide vaccines, and vector-based vaccines, have been 
employed to overcome this weak immunogenic response against T AAs (6). The idea of 
using these first generation cancer vaccines is primarily based on their ability to activate 
antigen-presenting cells (APCs) and stimulate antigen-specific cytotoxic T lymphocyte 
(CTL)-mediated immune response. In this context, dendritic cells (DCs), the most 
effective APCs, have been targeted to enhance their ability to activate T cells. In the last 
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several years, a variety of strategies have been employed to "instruct" DCs to induce 
robust immune responses against tumor antigens, thus breaking immune tolerance. The 
main focus of these strategies revolve around the efficient antigen-loading that include, i) 
infecting DCs with viral, bacterial, or yeast vectors, ii) pulsing DCs with proteins or 
peptides, iii) loading DCs with whole tumor cells or lysates, and iv) transfecting DCs 
with DNA or RNA. 
Viral, Bacterial and Yeast Vectors-based Vaccines: 
The common vectors used in the development of therapeutic cancer vaccines 
include virus, bacterial and yeast vectors. These vectors are used to deliver recombinant 
genes such as genes expressing T AAs, costimulatory molecules, and cytokines into 
APCs. As a result, these recombinant vectors may induce increased immune response 
against the gene of interest that has been inserted into the vector. Poxvirus vectors 
(vaccinia virus prototype) are among the most utilized vectors for the development of 
vaccines. The advantage of using these vectors is that they replicate within the cytoplasm 
of infected cells, which is important for the safe use of this vector as recombinant 
vaccines, and no genetic sequence from the virus will be inserted into the host genome. 
PSA-TRICOM, a poxvirus-based vaccine has been evaluated in 2 phase II clinical 
trials in patients with metastatic hormone-refractory prostate cancer (7). In the first trial, 
vaccinated patients had a greater 3-year overall survival and improved in median overall 
survival of 8.5 months when compared to the placebo controls. In the second phase II 
clinical trial at National Cancer Institute (NCI), patients vaccinated with PSA-TRICOM 
had improved median overall survival of 9.2 months. This study also suggested that 
Tregs playa significant role in the modulation of antitumor immunity. P ANV AC-VF, 
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another poxvirus-based vaccine, was also tested in a phase III clinical trial in patients 
with advanced pancreatic cancer (8). The vaccine is also under evaluation in several other 
CEA- or MUCl-expressing carcinomas. A pilot study at NCI has shown the tolerance of 
P ANV AC-VF in 25 patients with metastatic carcinomas. The vaccine generated an 
antigen specific T effector response in 3/8 patients measured by ELISPOT, tetramer, and 
intracellular IFN-y staining (9). 
In the last several years, a variety of different bacterial and yeast vectors have also 
been used for vaccine development. Among these, E coli, Salmonella, Yersinia, Shigella, 
Listeria monocytogenes, and Sccharomyces cerevisiae are the most investigated as 
vaccine vectors. The rationale for utilization of these microbes-based vectors as delivery 
vehicle for T AAs is primarily based on their ability to induce pro-inflammatory responses 
via interaction of pathogen-associated molecular patterns (PAMPs) with pattern-
recognition receptors (PRRs) expressed on APCs. These interactions are the key 
controller of the activation of innate and adaptive immune responses (10). Most 
importantly, by the utilization of genetic engineering and efficient fermentation 
technologies, these vectors can be used for the production of large-scale, cost effective 
antitumor vaccines. Although, viral and bacterial based vaccines showed some 
advantages, these systems have various limitations, such as requiring mitotic cell division 
for transduction, low maintenance of trans gene expression, and immune elimination of 
infected cells that limits gene expression in vivo. In addition, there are safety concerns 
arising from mutations in the transferred viral genome leading to virulent forms (11). 
Protein or Peptide-based vaccines: 
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The use of proteins or peptides has long been an attractive approach to stimulate 
an effective immune response against variety of cancers. This strategy covers a broad 
spectrum of possibilities of utilizing single protein or combination of proteins (12), fusion 
proteins, peptides, and agonist peptides (13, 14). The major advantages of using these 
protein or epitope-based strategies are their ease of production, storage, transportation 
and low cost. 
Recently, in the preclinical settings, we have demonstrated that both E7-peptide 
and E7 whole protein in combination with SA-4-IBBL, a costimulatory chimeric 
adjuvant based vaccine successfully eradicated the established TC-l tumors in over 70% 
of mice (15, 16). Survivin (SVN) protein based vaccine has also shown a promising 
outcome in eradicating the tumors in both transplantable and pulmonary lung metastases 
tumor models. In the clinical settings, Oncophage, a HSP gp96 peptide-based vaccine has 
been tested in two phase III clinical trials against melanoma and renal cell carcinoma 
(RCC) (17, 18). Although, in the first phase III clinical trials in melanoma patients 
vaccine was able to provide survival benefits after 10 or more vaccinations, but in the 
second clinical trial in RCC patients, no difference in recurrence-free survival or overall 
survival was observed between patients receiving Oncophage versus no treatment. 
Stimuvax, a MUC-I peptide-based vaccine which widely expressed on many tumors 
(lung, breast, prostate, colorectal), has also been evaluated in phase II B clinical trial in 
non-small cell lung cancer (NSCLC) (19) and showed positive signs of vaccine efficacy. 
Based on these data, Merck is currently conducting three large phase III clinical trials of 
Stimuvax. 
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Despite some promising clinical outcomes, use of specific proteins or peptides for 
the development of therapeutic vaccines clearly requires a careful selection of targeted 
T AAs, and their epitopes along with the ability to understand their structural and 
functional characteristics. Most importantly, this approach have certain drawbacks 
associated with it: i) weak immunogenicity ii) tumors can easily escape immune 
recognition through antigenic loss or mutation, iii) limited subset of patients due to HLA-
restriction, and iv) poor ability to activate balanced CD8+ and CD4+ T cell response. 
Whole tumor cells or tumor lysate-based vaccines: 
Theoretically, whole tumor cells contain all relevant T AAs and, as such, have the 
potential to elicit an effective anti-tumor immune response when administered in 
conjunction with an appropriate immunomodulator. In principle, these vaccines can have 
more advantages over the single-target approaches as it not only can target both different 
and unknown antigens at the same time but also able to stimulate robust adaptive immune 
responses due to availability of both MHC class I and class II epitopes. 
In the last two decades, several different vaccines derived from whole tumor cells 
or tumor lysate have been tested in both preclinical and clinic settings. In preclinical 
settings, vaccination with whole tumor cells was shown to stimulate the immune response 
through direct tumor-antigen presentation as well as prolonged release of T AAs that 
allow for sufficient tumor-antigen uptake by host APCs and subsequent activation of 
immune effector cells (20). Mice vaccinated with irradiated whole tumor cells in 
combination with an adjuvant, and subsequently challenged with non-irradiated tumor 
cells, were found to efficiently generate anti-tumor immune recall responses (21). In 
clinical settings, OncoVAX (Vaccinogen), an autologous irradiated tumor cells-based 
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vaccine has shown over 20% reduction in risk of colon cancer progression in patients 
compared to control groups. This efficacy was translated into improved overall survival 
of patients (22). Reniale, an autologous tumor cell lysate-based vaccine against RCC 
with adjuvant treatment showed greater benefits in patients with a higher risk. GV AX, 
another vaccine composed of two irradiated prostate cancer cell lines LNCaP and PC-3, 
has demonstrated some local immune responses in preclinical studies. Based on this 
encouraging preclinical study, it was further tested in clinical trials. Despite these 
encouraging immunological results, GV AX failed to meet the defined endpoint in two 
phase III clinical trials. 
However, despite containing all relevant T AAs and thus avoiding the problem of 
identifying appropriate tumor antigens, the use of autologous tumor cells for cancer 
vaccines also faces major limitations (23). In addition to the weak immunogenic nature of 
unmodified autologous tumor cell-based vaccines, the lack of sufficient tumor mass for 
vaccine preparation due to early detection as well as the inability to surgically access for 
certain cancers represent other limitations. Although tumor cells may be cultured for an 
extended time period to generate enough cells for vaccine preparation, the inability of 
certain tumor cells to grow under culture conditions poses another problem. As an 
alternative, allogeneic tumor cells have been used as a source of T AAs, which ideally 
would be taken up by APCs and presented to autologous immune effector cells. 
Potentially, this would provide a limitless source of TAAs through well established cell 
lines. Although allogeneic tumor cell lines allow for standardized and large scale 
production of potential cancer vaccines, such vaccines were demonstrated to direct the 
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majority of the immune response towards the alloantigens, and not T AAs, due to 
dominant antigenic competition, leading to inefficient anti-tumor immune responses (23). 
DNA and RNA-based vaccines: 
DNA-based vaccines formulated to encode TAAs and/or immunostimulatory 
molecules to elicit an effective anti-tumor immune response have emerged as a safer and 
advantageous alternative to gene therapy in both preclinical and clinical settings. In 
preclinical studies, intradermal injection of mice transgenic for rat neu and HER-2/neu 
homologue with rat neu cDNA in combination with plasmids encoding costimulatory 
molecules CD80lCD86 and 4-1BBL resulted in the induction of both cellular and 
humoral immune responses (24). Recently, several phase 1111 clinical trials have been 
conducted with DNA vaccines targeting variety of TAAs such as PSA, PAP, gplOO, 
CEA, HSP65 against prostate cancer (25), melanoma (26), colorectal cancer (27), and 
head and neck carcinomas (28). In most of the cases, these trials showed very low 
immunogenicity of TAAs. In another phase I clinical trial, Meian-AIMART-l DNA 
plasmid vaccine in patients with stage IV melanoma was well tolerated and induced an 
immune response. However, the vaccine did not induce regression of established disease 
(29). Despite pre-clinical and very low clinical success, the development of clinically 
successful naked DNA cancer vaccines faces major hurdles, such as the need for high 
doses of plasmid DNA, inefficient delivery of the gene of interest, low expression 
efficiency of the introduced gene, lack of vaccine efficacy, and finally safety concerns. 
In recent years, mRNA-based cancer vaccines are also breaking the grounds and 
are being used as an attractive immunotherapeutic approach against cancers (30, 31). The 
advantage of utilizing this approach is primarily because of its safety as transfected 
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mRNA does not integrate into the host genome (32). The principle behind this approach 
is that mRNA-based vaccine containing mRNA-coding TAA is transfected into DCs and 
translated into proteins which further processed and loaded on MHC for its presentation, 
thus activating an antigen-specific T cell response (33). Several clinical studies have been 
conducted by employing mRNA-based vaccine approach against different cancers such 
as prostate (34), RCC (35), ovarian (36), lung, breast (37), neuroblastoma (38) and 
melanoma (39). A phase I clinical trial with PSA-mRNA-based vaccine was able to 
increase PSA-specific CTL response against metastatic prostate cancer (40). In another 
clinical trial, vaccine containing DCs transfecting with total RNA extracted from clear 
cell carcinoma against metastatic RCC showed significant increase in tumor specific 
CD4+ and CD8+ T cells with simultaneous decrease in Treg frequency (36). 
Why vaccine fails: 
As mentioned above, although all the vaccine approaches have demonstrated 
efficacy in various preclinical studies, they have been either ineffective or demonstrated 
limited efficacy in clinical settings. These strategies are mainly associated with lack of 
specificity, inefficient delivery, safety concerns, labor intensive, costly, and in some cases 
patient-customized which severely limits their broad clinical applications. Among all the 
concerns, one of the major hurdles for the clinical success may be due to the lack of 
tumor specific antigens (TSAs) and/or weak immunogenic nature of TAAs, usually 
recognized by the immune system as self-antigen. Theoretically, TSAs, mostly composed 
of mutant proteins, are the ideal target for cancer vaccines due to their specificity; 
however, the major drawback of targeting TSAs is the uniqueness of these mutations to 
each tumor, potentially leading to the development of patient customized 
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immunotherapy. On the other hand, T AAs are commonly expressed on the tumors with 
same histology and are shared among tumors of different origins. But one of the major 
limitations associated with T AAs are their weak immunogenic nature due to the tolerance 
of self -antigens. The next major obstacle for clinical success may include active immune 
evasion mechanisms employed by progressing tumors. These obstacles may be overcome 
by using potent adjuvants/immunomodulators that not only boost the existing immune 
responses to the tumor in patients, but also generate new immune responses and, most 
importantly, overcome the immune evasion mechanisms. 
Why adjuvants are critical? 
The term "adjuvant" was first proposed by Ramos in 1920s which originated from 
the latin adjuvo means "to help". Adjuvants, substances that traditionally added to 
vaccines are used to enhance the magnitude, breadth, quality and longevity of the innate 
system to increase or modify a subsequent adaptive immune response, with minimal 
toxicity. Addition of adjuvants in the vaccine may substantially reduce the amount of 
antigen and/or number of immunizations required for optimum immune response. That is 
why, in the last several decades, adjuvants have been known to be a critical determinant 
of the success or failure of a vaccine and Charlie Janeway famously described the nature 
of adjuvants as "the immunologists dirty little secret". 
In the year between 1920s-1930s, it was found that aluminum salts can improve 
the immune response (41), thus Alum became the first vaccine adjuvant and until a year 
ago it has been the only approved adjuvant in USA for human vaccines. Adjuvants are 
necessary to boost the optimal immune response to weak antigens. Most importantly, 
adjuvants are important to overcome various tolerance mechanisms and facilitate the 
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induction of CTL response that can traffic to and lyse tumor cells. In this regard, the 
application of alum as adjuvant for cancer vaccines is limited (42) because alum-based 
vaccines primarily induce effective Th2 responses (43) with minimal efficacy in eliciting 
Thl immunity (44), which is necessary for the eradication of tumors. In this context, the 
choice of adjuvants is critical. Adjuvants can affect the nature of the elicited immune 
responses, such as Thl vs. Th2 responses, T cell vs. B cell responses, generation and 
maintenance of immunological memory, and reversal of the immunoregulatory 
mechanisms, such as Treg-mediated suppression and T cell anergy. As such, adjuvants 
that modulate innate, adaptive, and regulatory immunity in favor of the generation of 
effective anti-tumor immune responses may have the best efficacy. Of critical importance 
is the development of adjuvants with safety profiles in humans. Therefore, the 
development of effective therapeutic cancer vaccines for the clinic will require 
adjuvants/immunomodulators that can efficiently stimulate innate and adaptive immune 
responses as well as reverse/inhibit tumor-mediated immune suppressive mechanisms. 
Adjuvants for therapeutic cancer vaccines: 
In the last several years, despite the fact that adjuvants are the critical 
determinants of the success or failure of the vaccines, there has been great deal of 
pessimism regarding their use for the development of therapeutic cancer vaccines. This is 
mainly due to the lack of full characterization of mechanistic insight and precise 
knowledge of the constituents of many adjuvants until recently (45, 46). Some of the 
recently tested vaccine formulations, like viral vectors, are designed to express their own 
adjuvants while others, like peptide-based vaccines, do not and hence reqUlre co-
administration of adjuvants for the induction of potent immune response. 
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For the several decades, the choice of adjuvants available for cancer vaccines has 
been very limited, mostly or in part due to toxicity concerns raising significant regulatory 
hurdles. In fact, only aluminum-salt based adjuvants have been used for human use in the 
United States for decades until recently when combination of aluminum hydroxide with 
monophosphoryl lipid A (MPLA) has been licensed. Approval of recombinant vaccines 
against HPV and HBV, albeit in preventing setting, has provided a great hope for the 
development of several adjuvants to augment the efficacy of the cancer vaccines. As 
oppose to adjuvants whose characterizations are poorly understood, a growing focus has 
been shifting towards the use of natural ligands or synthetic agonists for well-defined 
PRRs as adjuvants. Among all PRRs, toll-like receptors (TLRs) are the largest and most 
well characterized family of a diverse set of germ line-encoded receptors which recognize 
broad classes of conserved molecular structures common to groups of microorganisms 
(47-49). 
Due to the critical role of TLR signaling on the innate, adaptive, and regulatory 
arms of the immune systems, TLR agonists have emerged as ideal adjuvants for cancer 
immunotherapy. Perhaps addition of various TLR agonists to vaccine formulations has 
been one of the most significant developments in the area of cancer vaccine. These 
agonists include TLR-3 (poly I:C), TLR-4 (MPL), TLR-5 (flagellin), TLR-7 (Aldara), 
TLR-7/8 (Resiquimod), and TLR-9 (CpG). Either alone or with various formulations, 
these TLR agonists have been shown to enhance the vaccine efficacy. In case of 
preclinical studies, these agonists have been demonstrated to generate anti-tumor 
immunity by enhancing innate immunity through the activation of DCs, NK cells, 
monocytes, and macrophages and induction of cytokines with both direct and indirect 
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anti-tumor activity. Engagement of TLRs on APCs, such as DCs, results in their 
maturation and migration to lymph nodes where they initiate adaptive immune responses 
and generate long-lasting memory against tumors. In case of clinical studies, MPLA has 
already been licensed in United States by FDA and used as a component of Melacine, 
Cervarix, a preventive HPV vaccine by GlaxoSmithKline Biological (GSK) (50), and is 
also a component of NSCLC vaccine in late-stage clinical trials. RC-529 (GSK, 
DynaVax), another synthetic TLR-4 agonist has been licensed for an HBV vaccine in 
Europe (51). CpG oligodeoxynucleotides (ODN) has also shown great promise as an 
adjuvant for TAA-based cancer vaccines (52). 
Despite some promising clinical results, safety profile of these TLR agonists has 
been of the major hurdles which need to be addressed for the use of these agonists as a 
component of vaccine formulations. TLR agonists as components of vaccines have been 
found to be associated with severe toxicity, resulting from non-specific activation of 
lymphocytes and plausibly from signaling into non-immune cells (53-55). The limited 
effect of TLR-signaling on the induction of adaptive immunity, which is critical to the 
establishment of long-term immunological memory and prevention of tumor recurrences, 
have also been one of the major challenges for these agonists to be used as an adjuvant 
component of therapeutic cancer vaccines (56-58). Most importantly, TLR-signaling has 
been found to be involved in the generation of regulatory immunity which plays a critical 
role in immune evasion and allow tumors to counterbalance the anti-tumor immunity. For 
example, TLR-4 signaling has been found to expand Tregs ex vivo and induce IL-IO 
producing CD4+ Tregs in vivo (54). Similarly, CpG, a TLR-9 agonist was involved in the 
conversion of CD4+ T effector cells into Tregs via plasmacytoid DCs (59), and was 
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found to induce CDI9+ dendritic cells to acquire potent T cell suppressive functions 
through the production of indoleamine 2,3-dioxygenase (60). Based on above discussed 
outcomes, there is a dire need for the discovery and development of alternative adjuvants 
which not only has the potent immunomodulatory activities on cells of innate, adaptive, 
and regulatory immunity but also provides safety without significant toxicity at 
therapeutic doses. 
Costimulatory 4-1BBL and OX40L as a platform for the development oftherapeutic 
cancer vaccines: 
An effective therapeutic cancer vaccine should aim to generate anti-tumor 
immunity by targeting T cells, APCs, and NK cells to eliminate the existing tumors and 
to promote immunological memory that prevents the recurrences. Most importantly, 
therapeutic cancer vaccine should also ideally prevent the generation and/or function of 
Tregs. In this context, costimulatory molecules ofTNFR super-families play critical roles 
in modulating innate, adaptive, and regulatory immune responses. Several preclinical 
studies have demonstrated the effectiveness of agonists that express the extracellular 
functional domain of TNF ligands and cross-link their costimulatory receptors for 
effective signal transduction (61,62). 
In recent years, there have been growing interests in two costimulatory molecules, 
4-1BB and OX40, which are shown to function primarily on CD8+ and CD4+ T cells, 
respectively. It is well known that signaling through 4-1BB and OX40 induces very 
similar responses although not identical. OX40 is expressed early after CD4+ T cell 
activation and mediates the effector T cells differentiation (63). Similarly, stimulation of 
4-1BB induces very identical effects on CD8+ T cells (64). Nevertheless, signaling 
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through these two costimulatory pathways have shown to overlap in their effects on both 
CD4+ and CD8+ T cells (65, 66). Agonistic ligands to these costimulatory receptors have 
been, either alone or in combination, widely tested as effective adjuvants of therapeutic 
cancer vaccines in both preclinical and clinical settings (62, 67). OX40 ligation has been 
shown to induce T cell mediated antitumor responses against variety of tumors including 
sarcoma, colon, breast, and prostate cancer (62, 68, 69). On the other hand, 4-1BB 
ligation has shown effects on DC activation, survival, cytokines such as IL-6 and IL-12 
which results into robust T cell stimulation (70, 71). Most importantly, 4-1BB ligation 
renders T effector cells resistant to suppression by Tregs (15) while OX40 directly 
inhibits the Tregs suppression (72). These agonistic antibodies induce robust 
amplification of T cell mediated immune responses, inhibit apoptotic cell death (73, 74) 
and stimulate long-lived T cell responses (75). In most of the studies, the anti-tumor 
responses generated by these agonists are associated with increased activity of CD8+ and 
CD4+ T effector functions. However, the biggest drawback with the use of agonistic 
antibodies for costimulatory molecules lies in their involvement in the induction of severe 
toxicity. These toxicities primarily arise from nonspecific, and systemic activation of 
lymphocytes (76, 77). These toxicities have further shown to be associated with cytokine-
mediated disruption of lymphocyte trafficking, splenomegaly, multifocal hepatitis, and 
lyphodenopathy (78, 79). Additionally, immunization of agonistic anti-CD28 monoclonal 
Ab has found to be lethal due to systemic inflammatory responses in a phase I clinical 
trial (80). Therefore, utilization of agonistic Abs as a component of therapeutic vaccines 
requires a rigorous scrutiny due to its potential toxicity in humans and demands the 
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development of agonists that provide appropriate immune signal transduction in the 
absence of toxicity. 
In this context, recently we have proposed the utilization of natural ligands as an 
alternative to agonistic Abs that may have both qualitative and quantitative differences in 
the generation of potent immune signal transduction with superior therapeutic efficacy in 
the absence of severe toxicity. Due to limitation of these ligands to be functional only as 
membrane bound proteins, not in soluble form, we have previously generated a chimeric 
4-1BB ligand (SA-4-IBBL) by fusing its functional extracellular domain to a modified 
form of core streptavidin (SA) for potent signal transduction. Due to virtue of SA, this 
chimeric protein exists in stable tetramers and higher structures and allows this ligand for 
the generation of potent immunological activities in soluble forms. The activity of this 
natural SA-4-1BBL has already been established in our lab (81) and has been 
demonstrated to be superior to agonistic anti-4-1BB Ab (3H3) in terms of qualitative and 
quantitative differences (79). SA-4-1BBL in combination with both E7 peptide and 
protein (TAA)-based vaccines demonstrated potent efficacy by eradicating> 70% of E7-
expressing TC-l tumors (15, 16). Based on our previous observations, we sought to 
determine if SA-4-1BBL can be utilized as a successful vaccine adjuvant in other tumor 
model with different TAA and if efficacy of SA-4-1BBL based vaccine can further be 
improved by addition of another immunemodulator in the vaccine formulation. 
Therefore, the first major goal of this Ph.D. dissertation was to test the therapeutic 
efficacy of SA-4-1BBL in combination with survivin (SVN), a bona fide self-TAA in 
3LL lung carcinoma model and determine the mechanistic insight of vaccine efficacy. 
The second goal was to determine the efficacy of SA-4-1BBL in combination with 
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another immunomodulator such as TLR-4 agonist MPLA and costimulatory SA-OX40L, 
due to their distinct mode of action, in different preclinical tumor mice models. 
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CHAPTER 2 
SA-4-1BBL AS AN ADJUVANT COMPONENT OF A VACCINE CONTAINING 
RECOMBINANT SURVIVIN INDUCES POTENT ANTI-TUMOR EFFICACY IN 
A CDS+ T CELL AND NK CELL DEPENDENT MANNER 
Introduction 
Cancer remains one of the deadliest diseases despite progress in the discovery of 
various strategies with the limited effects. The limited efficacy of these current treatment 
modalities are often due to their association with adverse side effects arising from lack of 
specificity for tumors, and most importantly their failure of eliminating residual and 
micrometastatic tumors, which can lead to recurrences (1). In this scenario, therapeutic 
vaccines based on tumor associated antigens (TAAs) are preferred alternatives to these 
conventional treatments for cancer primarily because of their safety profile and 
generation of long-term immunologic memory critical for the control of recurrences, 
which are the main cause of death from cancer. In order to succeed, vaccination against 
T AAs requires targeting the right T AA. The main properties of an ideal target T AA 
should be: i) over-expressed in tumors but little or undetectable in normal tissues, ii) 
essential for the survival of the tumors so that tumor immune escape can be avoided, and 
iii) expressed in many tumors so that vaccine could target variety of cancers. In this 
context, survivin (SVN) is known as one of the very few candidate T AAs that meet all 
these criteria (82). 
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SVN is a 16.5kD protein which is the smallest member of the inhibitor of 
apoptosis proteins (lAP) family. It is involved in the suppression of apoptotic cell death 
along with the regulation of cell division (82). SVN is expressed transiently in normal 
cells while constitutively expressed in most human cancers and its over-expression 
correlates with tumor progression and constitutes a poor patients survival (83, 84). It is 
now known that SVN can generate cellular immune response as several SVN-derived 
peptide epitopes that stimulate major histocompatability complex (MHC) class I 
restricted cytotoxic T lymphocytes (CTLs) have been identified in both cancer patients 
and in tumor-bearing mice (85-87). Since SVN-specific CTLs were able to target the 
tumor cells, it is suggested that potential tolerance to self-antigen can be effectively 
overcome and SVN-based immunotherapy can further be exploited in the clinic. 
However, the development of successful therapeutic vaccines based on SVN has 
not been fully realized as they have failed to mount an optimal clinical effect in a broad 
patient population. The efficacy of such vaccines is curtailed by the weak antigenic 
nature of SVN due to its potential immune tolerance to dominant epitopes and various 
immune evasion mechanisms employed by the progressing tumors. To overcome these 
limitations, therapeutic vaccine formulations containing SVN requires the inclusion of 
potent adjuvants that not only generate robust immune responses with long-term 
immunological memory, but also overcome various immune evasion mechanisms. In this 
context, we recently hypothesized that costimulatory ligands, particularly 4-1BBL can be 
exploited as potential adjuvant of choice for the development of therapeutic cancer 
vaccines as it plays a crucial role in the generation and maintenance of CD8+ T cell 
responses which is critical for the eradication of tumors (15, 16). 
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4-1BBL is known as one of the most potent costimulatory ligand of tumor 
necrosis factor (TNF) family due to its pleiotropic effects on variety of cells of innate 
(71), adaptive (88) and regulatory immunity (89). Inasmuch as 4-1BBL is a cell surface 
membranous protein and has no function in soluble form, recently we generated a 
chimeric protein, from hereafter called as SA-4-1BBL, by fusing the extracellular 
functional domain of 4-1BBL to a modified form of core streptavidin (SA). This soluble 
SA-4-1BBL has shown potent immune activity as an adjuvant component ofTAA-based 
vaccines by targeting various cells of innate, such as Des, NK cells, and adaptive, such 
as CD4+ and CD8+ T cells, in various preclinical tumor models (15, 16). Most 
importantly, SA-4-1 BBL also modulates regulatory immunity by reversing tumor 
induced clonal anergy, renders T effector cells resistant to suppression by 
CD4+CD25+FoxP3+ regulatory T cells, and inhibits the conversion of T effector cells 
into Tregs through the production ofIFN-y. 
We hypothesized that SA-4-1BBL can be exploited for the development of 
therapeutic vaccines by targeting SVN self-T AA expressed by most of the tumors. Here 
we report that single vaccination with SVN+SA-4-IBBL based vaccine resulted in the 
significant eradication of SVN expressing 3LL tumor. The efficacy of vaccine was 
mainly dependent on CD8+ T cells and NK cells effector function but not on the CD4+ T 
cells. This efficacy was further improved to complete tumor eradication when an 
additional vaccination was administered 6 days after the first vaccination. This improved 
efficacy was correlated with increased level of IFN-y and cytotoxicity. Additionally, 
SVN+SA-4-1BBL based vaccine also generate an effective humoral response without a 
sign of autoimmunity. These results provide the mechanistic insight of SVN+SA-4-1 BBL 
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vaccine in 3LL tumor model and emphasize the critical role ofCD8+ T cells and NK cells 
in the vaccine efficacy. These observations also demonstrate the utility of additional 
vaccinations for the optimal efficacy of self-T AA-based vaccine strategy that can target 
variety of tumors and can successfully be translated into clinic. 
Materials and Methods 
Mice and cell lines 
C57BLl6 and C57BLl6.SJL mice were purchased from The Jackson Laboratory, 
Taconic, or bred in our barrier animal facility at the University of Louisville. All animals 
were cared for in accordance with institutional and National Institutes of Health (NIH) 
guidelines. The 3LL, TC-l and A20 cell lines were purchased from American Type 
Culture Collection (Manassas, VA). 
Cloning, expression, and purification of recombinant SVN 
Mouse-cDNA was sub cloned into the pTWIN-I-6X-His bacterial expression 
vector (New England Biolabs) using Nde I and BamH I restriction sites. After 
transformation into C2566 competent E. coli cells (New England Biolabs), cultures were 
grown at 37°C and induced using IPTG. Cells were harvested 3 h after induction, 
pelleted, and resuspended in 100 ml of lysis buffer (2OmM Tris, pH 7.0, 500mM NaCl, 
5mM imidazole, 5mM ~-ME, IOIlM ZnC12). Cells were lysed by ultrasonication and 
inclusion bodies and insoluble material were pelleted at 10,000xg for 10 min. Pellet was 
washed three times by resuspending in lysis buffer containing 1 % Triton X-I 00, rotating 
30 min at room temperature, and repelleting at 35,000xg for 30 min. The final pellet was 
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resuspended in 100 ml lysis buffer containing 6M Guanidine-HCI and rotated at RT 
overnight to solubilize inclusion bodies. After, centrifugation at 35,000xg for 30 min at 4 
°C to remove the insoluble material, supernatant collected for IMAC purification using 
Talon® cobalt resin according to the manufacturer's protocol (Clontech) with the 
exception of including 0.1 % Triton X-114 to remove endotoxin. All purification steps 
were performed in the presence of 10JlM ZnCl2 and 5mM ~-ME to assist with proper 
folding and reduce oligomerization. Protein was dialyzed against PBS, concentrated 
using an Amicon Ultra MWCO 10,000 and sterile filtered using a 0.22Jlm filtration 
device. Protein concentration was measured using BCA and Bradford methods (Pierce). 
Construction, expression, purification, and characterization of SA-4-1BBL have been 
previously described (15). All the proteins had undetectable levels of endotoxin (SVN = 
0.066 EU/Jlg protein, SA-4-1BBL=0.004 EU/Jlg protein). 
Tumor models and immunizations 
C57BLl6 mice were inoculated s.c with 1x105 live 3LL cells into the right flank. 
For therapy, mice were vaccinated s.c. on day 6 post-tumor challenge with either SVN 
protein (50 Jlg) alone or with SA-4-1BBL (25 Jlg). For the two vaccination therapy, 
booster was administered either 3 days or 6 days or 9 days after first vaccination. Tumor 
size was measured with caliper twice a week. Tumor progression was determined by 
survival of mice which was defined when either tumor reached a size of 12 mm in 
diameter or when tumors ulcerated or mice showed signs of discomfort, at which point 
they were euthanized. 
Intracellular cytokine assay 
For intracellular cytokine staining, lymph node cells were resuspended in MLR 
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medium at 2x106/ml and stimulated with PMA (5 ng/ml, Sigma) and ionomycin (500 
ng/ml, Sigma) for 2 hrs in a 37°C, 5% CO2 incubator. GolgiPlug (1 J,ll/ml, BD 
PharMingen) was added to the activation mixture and cells were incubated for an 
additional 4 hrs. Cells were then stained with anti-CD44-APC and anti-CD8-APC-Cy7, 
fixed with 4% paraforrnaldehyde, and stained with anti-IFN-y-PE-Cy7 or isotype 
controls. FACS Caliber or LSR-II (BD Bioscience) was used for FACS acquisition 
followed by data analysis using CellQuest (BD Biosciences), FlowJo (Tree Star), and 
Diva (BD Biosciences) software. 
In vitro CTL and NK cells killing assays 
For in vitro cytotoxicity assay, long-term tumor free animals from SVN alone and 
SVN+SA-4-1BBL groups were boosted and one week post vaccination, spleen was 
harvested and splenocytes were cultured with 10J,lg SVN protein per ml in complete 
MLR medium supplemented with 50 IU/ml of IL-2. Five days post culture; viable 
lymphocytes (effector cells) were recovered by centrifugation over a Ficoll gradient. 
Effector cells were then collected and tested for cytotoxic activity against eH]-thymidine 
labeled 3LL tumor target for CTL killing and YAC-l tumor target for NK cell killing, 
respectively at various Effector/Target (E:T) for 4 h. 
In vitro lymphocyte proliferation 
Splenocytes from naive and long term boosted mice were cultured (2x 1 05/well) 
with 5 jlg/ml of soluble SVN protein for 5 days in complete MLR medium. Cultures 
were pulsed with eH]-thymidine for the last 16 hrs of the culture period, and harvested 
on a Tomtec Harvester 96 (Tomtec Inc., Harnden, CT) for quantification of incorporated 
radioactivity. Results were expressed as mean ± SD cpm of triplicate wells. 
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Depletion assay 
A depleting Ab against mouse CD8+ T cells (500uglmouse, Clone 53.6.72, 
Bioexpress), NK1.1 (500uglmouse, Clone PK 136, Bioexpress), and CD4+ T cells 
(300uglmouse, Clone GK1.5, Bioexpress) were used via intra peritoneal injection to 
deplete CD8+ T cells, NK cells and CD4+ T cells one day before vaccination. The 
depletion of these cells was complete as monitored at day 5 post treatment. 
Detection of antibodies 
Anti-SVN antibody was detected in mouse sera using enzyme-linked 
immunosorbent assay (ELISA). In brief 50 ng of SVN was coated on a 96-well plate by 
overnight incubation at 4 0c. Plate was washed and blocked followed by incubation with 
serum samples for 1.5 hrs at room temperature. Plate was washed and incubated with 
anti-mouse IgG conjugated with horseradish peroxidase (HRP) for 1 hr followed by 
incubation with substrate for 20 min. Reaction was stopped by sulfuric acid and measured 
on spectrophotometer at 490 nm. 
For autoantibody detection against ssDNA, ELISA was performed. In brief, plate 
was coated with 1J.lglwell of heat-denatured calf thymus DNA (ssDNA, from Sigma). 
Plate was washed twice followed by blocking with buffer containing 5% BSA + 0.5% 
Tween 20 + 0.1 % nalve B6 serum. Serum dilution was added to the plate followed by 
incubation at 4 DC for overnight. Plate was washed 3 times followed by addition of anti 
mouse IgG-HRP and absorbance was measured at 450nm. 
Statistics 
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Statistical analyses were perfonned using the One Way Anova, and Kaplan-
Mayer curves test using SPSS software. For each test, P values have been displayed and 
less than 0.05 and 0.001 were considered significant (*) and very significant (**), 
respectively. 
Results 
Expression and purification of recombinant SVN 
We generated plasmid encoding the pTWIN-1 expression vector, which contains 
mouse SVN cDNA and 6X-His residues at C-tenninus (Fig. 1A). The recombinant SVN 
was expressed in bacteria as inclusion bodies, denatured with Guanidine-HCI, and 
purified using IMAC taking advantage of a C-tenninus 6X-His tag. The purified protein 
runs approximately as a 16.5 kDa band on SDS-PAGE (Fig. 1B top panel) and reacts 
with SVN antibody when analyzed on western blot (Fig. 1B bottom panel). 
Next we tested if the 3LL cell line we are planning to use for this study expresses 
SVN. We looked at the expression of SVN in both cell lysate and supernatant from 3LL 
cell line along with other tumor cell lines like TC-1 and A20. As shown in Figure 2, cell 
lysate from all the cell line scored positive for SVN (Fig. 2A) while we did not see SVN 
expression in supernatant for either cell lines (Fig. 2B). These observations are consistent 
with SVN being a universal T AA. 
Single vaccination with SVN+SA-4-1BBL eradicated 3LL tumor and this efficacy 
was primarily dependent on CDS+ T cells with partial involvement of NK cells 
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First we evaluated the therapeutic efficacy of SVN+SA-4-1BBL vaccine in 3LL 
tumor model. C57BLl6 mice were challenged s.c. with 1x105 live 3LL cells and 
vaccinated once with either SVN alone (50 ~g) or with SA-4-1BBL (25 ~g) six days 
post-tumor challenge. Tumor growth and lifespan of the mice were followed for over a 
90-day period. As shown in Figure. 3, SVN+SA-4-1BBL vaccine was able to eradicate 
tumors in approximately 70% of mice while efficacy of SVN alone could only reach to < 
20%. In contrast, all PBS control mice were expired within 60 days. 
The therapeutic efficacy of the vaccine was associated with robust CD8+ T cells, NK 
cells effector and T cell proliferative responses 
One of the major reasons for the failure of current tested SVN-based vaccines in 
the clinic is due to their limited ability to mount optimal CD8+ T cells effector response 
on a broad patient population. The importance of T cell in the successful therapy can be 
deduced from this fact that the strategies which augment T cell effector responses to 
weak tumor antigens can only be translated into effective therapy (90). Therefore we 
evaluated the impact of SVN+SA-4-1BBL vaccine on CD8+ T cells effector response by 
measuring the IFN-y in the long-term tumor free animals one week after boosting with 
SVN+SA-4-1BBL. As shown in Figure 4A, long-term mice subjected to SVN+SA-4-
1BBL vaccine had significantly enhanced number of CD8+ T cells expressing IFN-y as 
compared to naIve mice, which translated into a robust SVN-specific CTL killing 
response against 3LL targets (Fig. 4B). 
As we (unpublished data) and others have already demonstrated that 3LL cells 
acquire low level ofMHC class I (91, 92) as a means to escape CTL and survive. As cells 
missing or low expression of MHC class I molecules lose resistance to NK cells and 
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become susceptible to NK cell-mediated lysis (93, 94), we next tested the role of NK 
cells on vaccine efficacy. We performed the NK cell specific killing assay against YAC-1 
targets and observed a significant higher killing at all E:T ratios in mice subjected to 
SVN+SA-4-1BBL as compared with naIve mice (Fig. SA). 
We also tested if long-term animals are able to generate T cell proliferation 
response after SVN exposure. To determine SVN-specific proliferation response, 
splenocytes from naive and long term boosted mice were cultured in the presence of 
soluble SVN protein for S days. As shown in Fig. SB, long-term boosted mice generated 
significantly higher SVN protein-specific in vitro lymphoproliferative response as 
compared with naIve animals. 
Taken together, these data suggest the requirement of both CD8+ T cells and NK 
cells for the success ofSVN+SA-4-1BBL based therapeutic effects. 
CDS+ T cells are critical while NK cells also play an important role in the efficacy of 
SVN+SA-4-1BBL vaccine 
As SVN+SA-4-1BBL vaccine was able to generate potent CD8+ T cells effector 
response with moderate NK cell killing response, which correlated with the therapeutic 
efficacy, we next depleted these cells to evaluate the direct involvement of these cells in 
the efficacy of vaccine. As shown in Figure 6, depletion of CD8+ T cells completely 
abrogated the efficacy of the vaccine as all CD8+ T cells depleted animals died before day 
SO due to tumor burden or discomfort. NK cells were also found to be a key player in the 
efficacy of vaccine as depletion of NK 1.1 attenuated the survival of the mice from 80% 
to 40%. We did not find any involvement of CD4+ T cells as depletion of these cells did 
not affect the efficacy of the vaccine. 
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Additional vaccination improved the therapeutic efficacy of the vaccine and this 
efficacy was dependent on the timing of the vaccine 
We next evaluated if additional vaccine will further improve the therapeutic 
efficacy of the vaccine. Therefore, we boosted the animals with SVN alone or SVN+SA-
4-1BBL at various time points. As shown in Figure 7A, an additional booster of 
SVN+SA-4-1BBL on day 12 (6 days after first vaccination) improved the survival of the 
mice to 100% while SVN alone could improve the efficacy to only 25%. Interestingly, 
the timing of booster was critical to vaccine efficacy as booster on day 9 and day 15 
could not improve the survival benefit over one vaccination (Fig. 7B). Although we 
observed attenuated therapeutic efficacy of vaccine on day 9 booster than single 
vaccination, it did not reach to a significant level. 
Taken together, these data suggest that prime-boost regimen is required and 
timing of the boost is critical for the optimal SVN+SA-4-1BBL vaccine efficacy in 3LL 
model system. 
Improved efficacy with additional vaccination was associated with CDS+ T cells 
effector function, but not the NK cells 
Our earlier data of in vivo depletion (Fig. 6) demonstrated the critical role of 
CDS+ T cell in the therapeutic efficacy of the SVN+SA-4-1 BBL vaccine. Therefore, we 
next evaluated the mechanistic basis of this therapeutic advantage of additional booster 
by measuring the CDS+ T cell effector responses. As shown, this therapeutic advantage 
was strictly due to increased CDS+ IFN-'t T cell (Fig. SA) and cytotoxic responses (Fig. 
SB), while NK cell response was not changed when compared with one vaccination (Fig. 
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SC). Taken together, these data suggest that additional vaccination enhance antitumor 
immunity by increasing the CDS+ T cell effector function but not the NK cell response. 
SVN+SA-4-1BBL-based vaccine generated humoral response without any sign of 
autoimmunity 
Recently, involvement of humoral immune response to tumor immunotherapy has 
been widely appreciated (95, 96), especially after the approval ofHerceptin, an antibody-
based vaccine, as a part of treatment regimen against Her2 expressing breast cancer. 
Therefore, we further investigated if SVN+SA-4-IBBL vaccine could also augment the 
humoral response. Sera from vaccinated mice were analyzed for titer to SVN-specific 
antibody. As shown in Figure 9A, SA-4-IBBL mediated co stimulation triggered the 
humoral response when compared with SVN alone. 
We also evaluated the effect of SVN+SA-4-IBBL vaccine on sign of 
autoimmunity as one of the major issues with the utility of self-antigens is the induction 
of autoimmunity which could be detrimental to the patients. Therefore, we tested the 
presence of autoantibody in the sera of vaccinated mice. As shown in Figure 9B, SVN-
SA-4-1 BBL vaccine did not generate antibody against ssDNA as compared to sera from 
lupus animals as a positive control. 
Discussion 
The efficacy of TAA-based therapeutic vaccine depends on the utility of 
immunogenic antigens and potent adjuvants which increase the breadth and intensity of 
the immune response of the vaccine. In the present study, we provide the evidence of 
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mechanistic role of the SVN+SA-4-1 BBL vaccine and demonstrate that two vaccination 
of this novel tumor vaccine results in the 100% survival of mice against 3LL tumors. This 
level of efficacy, to our knowledge, has never been achieved before with SVN. The 
efficacy of vaccine is associated with CD8 and NK cell effector functions. Physical 
depletion of CD8, CD4, and NK cells suggests that CD8+ T cells are the most critical 
player in the vaccine efficacy while NK cells also have an important contribution but not 
the CD4+ T cells. Importantly, the efficacy of vaccine is dependent on the timing of the 
treatment. SVN+SA-4-1BBL also generate a potent humoral response without any sign 
of autoimmunity. 
In recent years, TAA-based therapeutic vaccines have emerged as one of the most 
attractive approach for the treatment of cancers. In this context, SVN has been 
extensively used as an ideal T AA target for immunotherapeutic approaches due to its 
high levels of expression in most of the cancers with potential clinical applications. Over-
expression of SVN correlates with tumor progression and constitutes a poor patients 
survival (83, 84). In fact the advantage of utilization of SVN for vaccine development is 
not only relying on its broad expression patterns on majority of tumors, but also on the 
fact that down-regulation or loss of its expression would hamper the tumor progression 
and/or enhance the tumor cell death. These virtues make SVN based immunotherapy an 
ideal approach to treat variety of cancers. However, the development of successful 
therapeutic vaccines based on SVN self-antigen has been very limited in terms of tumor 
eradication. In this regard, utilization of effective adjuvant as a part of vaccine 
formulation holds great importance for the vaccine success. Recently, we have 
demonstrated that costimulatory ligand SA-4-1BBL can be exploited as potential 
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adjuvant of choice for the development of therapeutic cancer vaccines against TC-1 
tumors (15, 16). Consistent with our previous study, here we demonstrate that SVN in 
conjunction with SA-4-1BBL costimulatory adjuvant resulted into an impressive efficacy 
in the eradication of 3 LL tumors in > 70% of mice while efficacy with SVN alone could 
reach to < 20%. The better efficacy of SVN+SA-4-1BBL was correlated with increased 
CD8+ T cells IFN-y response which resulted into the higher CTL and NK cell killing 
responses against 3LL and YAC-1 tumor cells, respectively. 
Our results further show that an additional booster vaccination improves the 
efficacy ofSVN+SA-4-1BBL vaccine from 70% to 100% in this model. Importantly, this 
improved efficacy of additional booster was correlated with increased CD8+ IFN-y+ T 
cells response and CTL cytotoxicity. Physical depletion of CD8+ T cells completely 
abrogated the therapeutic efficacy directly confirmed the critical role of CD8+ T cells in 
the vaccine efficacy in this model system. One of the major reasons for the failure of 
current tested SVN-based vaccines in the clinic is due to their limited ability to mount 
optimal CD8+ T cells response on a broad patient population. The importance of T cell in 
the successful therapy can be deduced from this fact that the strategies which augment T 
cell responses to weak tumor antigens can only be translated into effective therapy (90). 
In this regard, SVN+SA-4-1BBL vaccine utilized in this study has shown great promise 
due to virtue of SA-4-1BBL as it targets CD8+ T cell effector function which translates 
into an effective therapy (15). Role of CD8+ T cells generated by SVN+SA-4-1BBL 
vaccine in our study is in the agreement with several other reports which suggest that T 
cells mounts a vigorous cytotoxic response against survivin both in vitro and in vivo (97, 
98). Additionally, Xiang et al. (87) has also demonstrated that survivin-based DNA 
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vaccine induces potent antitumor response against Lewis Lung Carcinoma and efficacy 
of vaccine was dependent on antigen-specific CD8+ T cell response which triggered 
tumor cell apoptosis, together with release of IFN-y. SVN+SA-4-IBBL vaccination also 
enhanced the memory response evaluated by the increased SVN-specific T cell 
proliferation in the long-term animals suggested that vaccine has potential to check the 
recurrences. 
We next observed that vaccine was also able to generate NK cell killing against 
Y AC-1 target cells. Depletion of NK cells reduced the efficacy from > 70% to 40% 
further confirmed the involvement of NK cells in the efficacy of SVN+SA-4-IBBL 
vaccine in this model which was found to be additional mode of vaccine action. As we 
(unpublished data) and others have already demonstrated that 3LL cells acquire low level 
of MHC class I (91, 92) as a means to escape CTL and survive. Cells missing or low 
expression of MHC class I molecules lose resistance to NK cells and become susceptible 
to NK cell-mediated lysis (93, 94). This is consistent with the previous reports by several 
groups demonstrating the crucial role NK cells play in killing of class I negative tumors 
(99). 
Next our results show that timing of the additional booster vaccination is critical 
for the optimal vaccine efficacy. We administered the additional booster vaccination at 
different time points after the first vaccination and to our surprise, we found out that 
additional booster given 6 days after first vaccination was only able to improve the 
efficacy of vaccine while booster on 3 days or 9 days after first vaccine didn't affect the 
vaccine efficacy. This suggests that timing of the booster is critical for the optimal 
efficacy. Surprisingly, booster on 3 days (early) after first vaccination relatively, although 
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not significantly, lower the therapeutic efficacy of the vaccine when compared to single 
vaccination. Recently, it has been reported that, depending on the timing of the treatment, 
anti-4-1BB Ab can either cause activation-induced cell death (AICD) or enhance 
immunity in viral setting (100). When given early after infection, anti-4-1BB was 
immunosuppressive and associated with depletion of virus-specific CD8+ T cells while at 
the later time points; the CD8+ T cell response was augmented. 
One of the major concerns for self-T AA based immunotherapy is the potential 
autoimmune abnormalities. Next we demonstrate that SVN+SA-4-1BBL vaccine did not 
generate any sign of autoimmunity as we couldn't detect any autoantibody against 
ssDNA in the sera of the mice treated with vaccine. However, we detected higher SVN-
specific antibodies (humoral response) in the mice subjected to SVN+SA-4-1BBL 
vaccine. Although generation of anti-SVN antibodies following therapeutic immunization 
is currently not being seen as one of the predominant aspects of potential antitumor 
response, existence of circulating antibodies against SVN has already been reported in 
variety of human cancers (101, 102). Therefore, presence of these SVN-specific 
antibodies in the cancer patients may predict as a means of host defense against tumors. 
In this perspective, generation of SVN-specific humoral response by our vaccine may be 
advantageous from the therapeutic point of view. 
In conclusion, the vaccine strategy proposed in this study stand a chance of 
translating into the clinics as the operational approach employed in this study along with 
virtue of general applicability of our vaccine as a potent means of immunotherapy, 
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Western 
blot 
Production of recombinant mouse-Survivin. (A) Schematic representation of pTWIN-l 
expression vector with SVN, (B) Coomassie blue staining (top) and western blot (bottom) 
patterns ofIMAC purified recombinant SVN. 
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SVN expression on different tumor cell lines. Cell lysate (A) and culture supernatant (B) 
from TC-l, 3LL and A20 cell lines were prepared and analyzed using western blot. 
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Days post tumor challenge 
• 
SVN+SA-4-1BBL vaccine eradicates SVN expressing 3LL tumors. C57BLl6 mice were 
challenged with live 1x105 3LL cells and vaccinated once s.c. on day 6 post-tumor 
challenge with either SVN (50 )lg) alone or with SA-4-1BBL (25 )lg). ** P < 0.001 for 
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SVN+SA-4-1BBL based vaccine induces a strong antitumor CD8+ T cell response. Long-
term survived animals treated with SVN+SA-4-1BBL vaccine develop E7-specific CD8+ 
T cell effector response after boosting as determined by (A) increased CD8+ T cell 
intracellular IFN-y+ expression, (B) increased CTL killing. n = 3 or 4; ** P < 0.001 were 
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Figure 5 
SVN+SA-4-1 BBL based vaccme induces NK cell killing and T cell proliferation 
responses. Splenocytes from long-term survived animals boosted with SVN+SA-4-1BBL 
vaccine was cultured in the presence of IL-2 for 5 days to be used as effector cells and 
plated against Y AC-l target cells in various E:T ratios to determine the NK cell killing 
response (A). Splenocytes from above was also cultured with or without 51lglml SVN for 
5 days to determine SVN-specific proliferation (B). (n =3 or 4), * P < 0.05 were 
calculated using student t-test, ns = not significant. Data is representative of two 
independent experiments. 
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Days post tumor challenge 
Figure 6 
Efficacy of SVN+SA-4-lBBL based vaccine is mainly dependent on CDS+ T cells 
followed by NK cells but not on CD4+ T cells. The role of CDS+ T cells and NK cells in 
the efficacy of vaccine was evaluated by depleting these cells with single i.p. injection of 
anti-CDS (500 11 g), anti-CD4 (300 Ilg) and anti-NK1.1 (500 Ilg) Abs/mouse one day 
before vaccination. The depletion of these cells was complete as monitored at day 5 post 
treatment. ** P < 0.001 for SVN+SA-4-lBBL VS. SVN+SA-4-lBBL+anti-CDS Ab group 
while * P < 0.05 for SVN+SA-4-lBBL VS. SVN+SA-4-lBBL+anti-NKl.l Ab group. 
(This experiment was performed in collaboration with Rajesh Sharma). 
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Figure 7 



















o 10 20 30 40 50 60 70 80 90 
Days posttumorchallenge 
Additional vaccination of SVN+SA-4-1 BBL completely eradicates the tumor and this 
improved efficacy is dependent on the timing of the booster. (A) C57BLl6 mice were 
challenged with live lx105 3LL cells and vaccinated either once s.c. on day 6 or twice on 
day 6 and day 12 post-tumor challenge with either SVN (50 llg) alone or with SA-4-
1BBL (25 llg) (B) booster was also administered either 3 days or 9 days after the first 
vaccination. ** P < 0.001 for SVN+SA-4-1BBL two vaccine vs. SVN alone and PBS 
controls while * P < 0.05 for SVN+SA-4-1BBL two vaccine vs. SVN+SA-4-1BBL one 
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The increased therapeutic efficacy of booster vaccination is associated with improved 
CD8+ T cells effector response but not the NK cells as demonstrated by (A) improved 
CD8+ T cell intracellular IFN-'t expression, (B) increased CTL killing, but (C) no 
























SVN+SA-4-1BBL based vaccme induced SVN-specific antibody without sign of 
autoimmunityo (A) Sera from naIve (n=6) and long-term tumor free animals (n=6) were 
tested for SVN-specific antibody using ELISA. (B) Sera from above animals were also 
tested for autoantibodies against ssDNA. Sera from pooled (n=3) lupus animals were 
used as positive control. P values were calculated using student t-test. 
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CHAPTER 3 
SA-4-1BBL AND OX40L COMBINATION AS AN ADJUVANT SYSTEM SHOWS 
ROBUST THERAPEUTIC EFFICACY IN ESTABLISHED TC-l TUMORS 
Introduction 
One of the major advantages of utilization of vaccination strategy against cancers 
IS its ability to elicit an immune response to primary tumors and maintain an 
immunological memory upon the reoccurrences. Given the most solid tumors usually 
express MHC class I, but not MHC class II, role of CD8+ T cells in the eradication of 
tumors attracted more attention than CD4+ T cells. However, it is critical to consider the 
role of CD4+ T cells in the exertion of CD8+ T cell independent antitumor response as 
well as the generation and persistence of memory CTL responses for designing the 
vaccine against tumors. CD4+ T cells can induce antitumor immunity by recruiting and 
activating macrophages and eosinophils and this effect can be independent of CD8+ T 
cells (103, 104). CD4+ T cells generate IFN-y response which has antitumor or 
anti angiogenic effects (105). In contrast, CD4+ T cells also help enhancing the antitumor 
immunity of CD8+ T cells (l 06, 107). These above observations indicate the importance 
of CD4+ T cells in tumor immunotherapy and justify the design of vaccines that aimed at 
inducing a CD4+ T cell response for effective therapy. 
We started this study based on our previous observations with E7+SA-4-1BBL 
vaccine in TC-l tumor (16) and SVN+SA-4-1BBL vaccine (Chapter 2) in 3LL tumor 
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which suggests the lack of CD4+ T cells involvement in the vaccine efficacy. These 
findings could be interpreted as the inability of SA-4-1BBL-based vaccine to induce 
CD4+ T cells response or that CD4+ T cells do not play any role in the vaccine efficacy. 
We, therefore, addressed this issue by including an adjuvant with potent impact on CD4+ 
T cells in the SA-4-1BBL based vaccine formulation. In this regard, costimulatory 
OX40L was the primary adjuvant of interest due to its critical role on the generation of 
potent CD4+ T cell responses. 
Recently, the costimulatory OX40, a member of tumor necrosis factor receptor 
(TNFR) superfamily has been extensively studied as a potent antitumor agent. OX40 has 
been shown to be expressed by CD4+ T cells and CD8+ T cells (67, 108). OX40 has been 
widely studied on CD4+ T cells due to its high level expression after T cell activation. 
Signaling via OX40 has shown increased migration, increased cytokine production by 
effector cells, and increased numbers of CD4+ memory T cells (108-110). Agonistic 
ligand to OX40 receptor has been widely tested as effective adjuvant of therapeutic 
cancer vaccines in both preclinical and clinical settings. Administration of 
OX40Llimmunogiobulin fusion protein or OX40R mAb resulted in a significant 
prolongation of survival of tumor-bearing mice (62). In most of the studies, the antitumor 
responses generated by these agonists are associated with increased activity CD4 effector 
functions. Most importantly, OX40 signaling directly inhibits the Tregs suppression (72) 
makes it an attractive adjuvant for the development of therapeutic cancer vaccines. 
Therefore, we hypothesize that by providing CD4+ T cells help and targeting Tregs via 
OX40L will further enhance the antitumor efficacy of SA-4-1BBL vaccine which 
primarily targets the CD8+ T cells (Fig. 10). 
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In this study, we generated a novel fonn of OX40L by fusing the extracellular 
functional domain of this molecule to a modified fonn of core streptavidin (SA) to 
generate a chimeric molecule (SA-OX40L) that exists as tetramers and oligomers owing 
to the structural features of SA. We here in show that this chimeric SA-OX40L has 
preferential activity on CD4+ T cells in vitro while has activity on both CD4+ T cells and 
CD8+ T cells in vivo. 
Next, based on our previous observation of> 70% of therapeutic efficacy with 
SVN+SA-4-1BBL vaccine, we sought to improve this efficacy by combining SA-4-
1BBL with SA-OX40L which may further overcome the immune tolerance. A single 
vaccination of SA-4-1BBL and SA-OX40L combination as a part of E7-based 
therapeutic vaccine resulted into eradication of E7-expressing TC-1 tumors in 100% 
mice. The efficacy of the combination vaccine is correlated with higher antigen specific 
CD8+ T cell responses as compared to single agents. The combination vaccine was also 
able to eradicate 3-4 mm size TC-1 tumors in 50% of the mice while single agent has 
only 10% efficacy. Together, these data suggest that combination ofSA-4-1BBL and SA-
OX40L can be exploited to use as a new therapeutic vaccine strategy which has great 
promise to be successful in the clinic. 
Material and methods 
Mice and cell lines 
C57BLl6 and C57BLl6.SJL mIce were bred and maintained under specific 
pathogen-free conditions in our barrier animal facility at the University of Louisville. All 
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animals were cared for in accordance with institutional and NIH guidelines. TC-l cell 
line was purchased from ATCC (Manassas, VA) and maintained as published (15, 111). 
Antibodies and other reagents 
Fluorochrome-conjugated anti-CD8-APC-Cy7, anti-CD62L-PE, anti-CD44-APC, 
anti-TNF-PE, anti-IFN-y-PE-Cy7, and anti-IL-2-PerCp-Cy5.5, and isotype controls were 
purchased from BD Bioscience, eBioscience, and BioLegend. The HPV16 
RAHYNIVTF E7 peptide (E749-57), SA-4-1BBL, E7, and SA proteins were reported 
previously (15, 111) 
Construction and expression of chimeric SA-OX40L protein 
The extracellular functional domain of OX40L molecule was synthesized at 
GenScript USA Inc. (Piscataway, NJ). The accurate sequence for OX40L was digested 
with EcoRI and XhoI and subcloned into pMT-Bip-V5-HisA expression vector 
containing a 6x-His Tag and core streptavidin (SA) sequence as previously published 
(81). The chimeric SA-OX40L was expressed using Drosophila expression system (DES; 
Invitrogen Life Technologies) followed by purification using IMAC Sepharose column, 
endotoxin testing, and quantification. 
Receptor Binding Assay 
Receptor binding assay was performed as previously published (81). In brief, 
splenocytes were stimulated with 5 ~glml Con A (Sigma-Aldrich) in complete MLR 
media for 48 h. Naive or Con A activated splenocytes were then incubated with SA-
OX40L (200ngl106 cells) or molar equivalent of SA control protein on a shaker at 4 °c 
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for 30 min. Following incubation, cell were washed extensively, stained with CD4-APC, 
CD8-PercP and SA-FITC, and analyzed on flow. 
T cell proliferation assay 
Both CD4+ and CD8+ T cells were sorted from naive C57BLl6 mice and cultured 
separately with 0.25 Jlglml anti-CD3 (BD Biosciences) and irradiated syngeneic 
splenocytes in the presence of various concentrations of SA-OX40L or SA control 
proteins. After four days, culture was pulsed with eH]thymidine during the last 16 h of 
the culture and harvested on a Tomtec Harvester 96 for analysis. 
For in vivo proliferation assay, OT-I and OT-II (CD45.2) cells were labeled with 
2.5 JlM CFSE and 2x106 OT-I and OT-II cells were transferred by i.v. into naive 
C57BLl6-SJL (CD45.1). After 24h, mice were immunized s.c with OVA (3 Jlg) alone or 
with SA-4-1BBL (5 Jlg) or SA-OX40L (5 Jlg) or combination of both agents (5 Jlg+ 5 
Jlg). After 3 days, peripheral LNs were harvested and OT-I and OT-II proliferation was 
assessed by analyzing the CFSE dilution of CD45.2+CD8+ and CD45.2+CD4+ cells using 
flowcytometry. 
Tumor models and vaccination 
C57BLl6 mice were subcutaneously (s.c.) challenged with 1x105 TC-1 cells into 
the right flank followed by single s.c. vaccination on day 6 post-tumor challenge with 
various vaccine formulations containing E7 protein (50 Jlg) alone as control or with SA-
4-1BBL (25 Jlg), SA-OX40L (25 Jlg), or the combination of both adjuvants (25 
Jlgladjuvant). The diameters of tumors were measured with caliper and mice were 
euthanized when tumor reached a size of 12 mm in diameter, ulcerated, or mice showed 
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signs of discomfort. For depletion study, CDS+ and CD4+ T cells were depleted using 
Abs against CDS (clone 53.6.72) and CD4 (clone GK 1.5) at 500 J..lg/mice via intra 
peritoneal (i.p.) injection one day before vaccination. 
For therapy with established tumors, mice with -3-4 mm TC-l tumors were 
vaccinated with above described formulations twice at 5 days interval. Tumors were 
followed for maximum of 100 days or until mice were euthanized due to tumor reached a 
size of 12 mm in diameter, ulcerated, ormice showed any sign of discomforts. 
Flow cytometry 
Spleens and/or tumor draining lymph nodes (TdLNs) were processed as described 
previously (16). For memory T cell typing, lymphocytes were stained with anti-CDS-
APC-Cy7, anti-CD62L-FITC, and anti-CD44-APC Abs. For intracellular cytokine 
staining, lymphocytes (1xl06 cells/mL) were stimulated either with 10 J..lg/mL E749-57 
peptide or whole E7 protein for 2 hrs followed by incubation with GolgiPlug (1 J..lllmL, 
BD PharMingen) overnight. Cells were first stained with anti-CDS-APC-Cy7, anti-CD4-
Alexa700, and anti-CD44-APC, fixed with 4% paraformaldehyde followed by staining 
with anti-IFN-y-PE-Cy7, anti-IL-2-Percp-Cy5.5, or isotype controls. 
Results 
Generation of chimeric SA-OX40L with demonstrated activity in soluble form 
Under physiological conditions, cross-linking of costimulatory receptors by cell 
membrane-bound ligands is critical for potent signal transduction and immune cell 
activation. Due to this prerequisite, most of the costimulatory ligands have attenuated 
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activity in the soluble fonn. Although agonistic Abs to these receptors is effective in 
delivering immunological signals, we chose to use natural ligands since signals generated 
by agonistic Abs is associated with severe toxicity (79). Based on our previously 
constructed chimeric SA-4-1BBL molecule which has shown potent activity in the 
soluble fonn in the absence of severe toxicity (15, 79, 81), we generated a chimeric SA-
OX40L costimulatory molecule due to its critical role on both effector and regulatory ann 
of the immune system. 
The extracellular domain of mouse OX40L, which is critical for binding and 
delivery of immunological signals via its receptor OX40, was cloned C-tenninal to SA to 
ensure proper protein folding as OX40L is a type II membrane protein (Fig. l1A). This 
chimeric gene was then sub cloned into pMT-Bip-V5-HisA expression vector and 
expressed using Drosophila expression system. As shown in Fig. 11 B, under native 
condition SA-OX40L protein existed as tetramers and higher structures while under 
native condition it existed as monomers, owing to the structural characteristics of SA 
(Weber et al. Science, 1989). The chimeric SA-OX40L was able to bind OX40 receptor 
expressing on both activate CD4+ and CD8+ T cells while binding to naive T cells was 
undetectably low (Fig. 11 C). 
Soluble SA-OX40L induce T cell proliferation 
To evaluate the functional attributes of chimeric SA-OX40L in vitro, both sorted 
CD4+ and CD8+ T cells were stimulated with suboptimal anti-CD3 Ab in the presence of 
various concentrations of SA-OX40L. Costimulatory SA-OX40L was able to generate an 
effective proliferative response in CD4+ T cells (Fig. 12A) but not in CD8+ T cells (Fig. 
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12B). This response was both dose dependent and SA-OX40L specific as SA control 
protein fail to generate any response. 
We next tested the functionality ofSA-OX40L in vivo by utilizing OT-I and OT-
II system. As consistent with in vitro study, SA-OX40L generated a vigorous 
proliferative response in CD4+ OT-II cells. On the other hand, just oppose to in vitro 
study, SA-OX40L was able to generate CD8+ OT-I proliferative response in vivo but it 
was not as robust as OT-II proliferation (Fig. 13). 
Combination of SA-4-1BBL and SA-OX40L as the adjuvant component of E7 TAA-
based vaccine completely eradicates the E7-expressing TC-l tumors 
As previously reported, a single vaccination with E7+SA-4-1 BBL based vaccine 
was able to eradicate E7-expressing established TC-l tumors in > 70% of mice and this 
efficacy was preferentially due to the involvement of CD8+ T cell effector functions (16, 
112). Keeping the aggressiveness of TC-l tumors and utilization of single adjuvant in 
mind, this efficacy was turned out to be very impressive. Although, CD8+ T cells are very 
critical for the elimination of tumors, involvement of CD4+ T cells help cannot be 
ignored. Since 4-1BB signaling preferentially targets the CD8+ T cells, probably this 
could be a possible reason our previously reported E7+SA-4-1BBL vaccine couldn't 
reach to its optimal potential. Therefore, we hypothesize that whether the therapeutic 
efficacy of this vaccine can further be improved by modifying the formulation to include 
SA-OX40L as the second adjuvant with primary effect on the CD4+ T cells. A single s.c. 
vaccination with E7 protein mixed with SA-4-1BBL and SA-OX40L resulted in the 
eradication of TC-l tumors in all mice for 90 day observation period (Fig. 14). In 
contrast, monotherapy with SA-4-1BBL and SA-OX40L resulted in eradication of tumor 
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in only> 70% and > 60% of mice, respectively. Mice that expired from tumor in the 
single agent groups, however, had slow kinetics of tumor progression as compared with 
both PBS and E7 protein control groups where all mice expired from the tumor burden 
around day 60 (Fig. 14). Taken together, these data demonstrate that combination of SA-
4-1BBL and SA-OX40L formulation is effective in eradicating the TC-1 tumors than the 
individual agents. 
The therapeutic efficacy of SA-4-1BBL and SA-OX40L combination is associated 
with the CDS+ T cell effector and memory responses 
CD8+ T cell effector and memory responses are the key mechanisms immune 
system employ to eliminate the primary tumor and control the recurrences, respectively, 
in various tumor settings, including the TC-1 model (16, 113, 114). We, therefore, 
assessed the effect of combination vaccine on the CD8+ T cell effector and long-term 
memory responses. Mice that had eradicated the tumor in response to various vaccine 
formulations were boosted s.c. with the same formulations and intracellular cytokine 
response of CD8+ T cells to the dominant E749-57 epitope was tested one week later (15). 
In congruent with the therapeutic efficacy, combination of SA-4-1BBL and SA-OX40L 
generated a better antigen-specific cytokine response than single adjuvant therapy as 
assessed by CD8+ T cell expressing IFN-y single (Fig. 15A), and IFN-y IL-2 double 
cytokines (Fig. 15B). There was no significant difference found between SA-4-1BBL 
and SA-OX40L monotherapy at cytokine levels. Additionally, combination vaccine 
formulation also generated the most effective CD8+ T cell memory recall responses as 
compared to those including SA-4-1BBL and SA-OX40L as single agents (Fig. 15C). 
Most importantly, combination vaccine was also able to significantly reduce the 
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CD4+Foxp3+ Tregs in the spleen as compared to single agents (Fig. 15D). Combination 
vaccine was also able to generate better CD4+ and CDS+ T cell proliferation response in 
vivo as compared to single agents (Fig. 16). Collectively, these data demonstrate that 
combination of SA-4-1BBL and SA-OX40L generate potent CD4+ and CDS+ T cell 
proliferative and CDS+ T cell effector and memory responses that correlate with the 
therapeutic efficacy of the vaccine against the TC-1 tumor. 
CDS+ T cells are the most critical player followed by CD4+ T cells in the therapeutic 
efficacy of both SA-OX40L+SA-4-1BBL combination therapy as well as SA-OX40L 
monotherapy 
Due to generation of CDS+ and CD4+ T cells responses by SA-4-1BBL and SA-
OX40L, we used Abs against CDS and CD4 molecules to deplete CDS+ and CD4+ T 
cells, respectively. Mice with TC-1 tumors were treated with depleting Abs one day 
before vaccination with E7 in conjunction with combination ofSA-OX40L+SA-4-1BBL 
or SA-OX40L monotherapy. As shown in Fig. 17, depletion of CDS+ T cells almost 
completely abrogated (100% vs. 16%) while depletion of CD4+ T cells also significantly 
abrogated (100% vs. 40%) the therapeutic efficacy of SA-OX40L+SA-4-1BBL 
combination therapy. Depletion of CDS+ T cells (66% vs. 20%) and CD4+ T cells (66% 
vs. 33%) also significantly abrogated the efficacy of SA-OX40L monotherapy. Based on 
our previous data, depletion of CDS+ T cells completely abrogated the efficacy of the SA-
4-1BBL monotherapy while CD4+ T cell depletion doesn't affect the efficacy (data not 
shown). Taken together, these data provide direct involvement of both CDS+ and CD4+ T 
cells in the therapeutic efficacy of combination as well as SA-OX40L mono therapies. 
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Combination of SA-4-1BBL and SA-OX40L vaccine formulation eradicates the 
established E7-expressing TC-l tumors 
Next we tested if combination vaccine fonnulation is able to eradicate more 
stringent established tumors. Mice with 3-4 mm size of TC-l tumors were vaccinated 
twice on day 6 and day 12 with various vaccine fonnulations and followed for 100 days. 
As we expected, combination vaccine fonnulation was even able to completely eradicate 
3-4 mm TC-l tumors in 50% of mice (Fig. 18). In contrast, single agents were only able 
to eradicate tumors in > 10% of mice while all control mice died within 60 days. 
Discussion 
In this study, we demonstrated that the chimeric SA-OX40L had potent activity 
on both CD4+ and CD8+ T cells with preferential effects on CD4+ T cells in vivo. Next, 
we demonstrated that addition of SA-OX40L in SA-4-lBBL vaccine fonnulation further 
improved the efficacy of the vaccine to 100% in TC-l cervical cancer model. The 
efficacy of combination therapy was associated with robust primary CD8+ T cell effector 
and long-tenn memory as well as CD4+ T cell responses. Most importantly, the 
combination vaccine was also able to eradicate the more stringent 3-4 mm large TC-l 
tumors in 50% of mice. 
The choice of addition of OX40L, another member of costimulatory TNF ligand 
family, to SA-4-lBBL based vaccine was due to its potent effects on CD4+, CD8+ T and 
Tregs with preferential influence on CD4+ T cells. As SA-4-lBBL primarily targets the 
CD8+ T cells, attaining an additional CD4+ T cells help is expected to improve the 
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therapeutic efficacy of the vaccine as CD4+ T cell help is essential for generation of 
primary CD8+ T cell response (115, 116). We chose to generate SA-OX40L instead of 
using already available agonistic anti-OX40 Ab due to qualitative and quantitative 
differences between natural ligand and agonistic Abs (79). As we expected, the generated 
chimeric SA-OX40L was able to induce potent CD4+ and CD8+ T cell proliferative 
response with preferential effect on CD4+ T cells, which is consistent with previous 
studies with anti-OX40 Abs. Most importantly, combination of SA-4-1BBL and SA-
OX40L was able to generate potent proliferative responses in both CD4+ OT-II and CD8+ 
OT-I cells in vivo. This efficacy further translated into a better therapeutic outcome 
against established TC-l tumors. 
The therapeutic outcome may be contributed by several mechanisms including 
synergy between 4-lBB and OX40 signaling. Although 4-1BB co stimulation strongly 
targets the CD8+ T cells while OX40 targets CD4+ T cells, there is considerable overlap 
in their expression and functional mechanisms. Due to wide cellular distribution of these 
two receptors, it may increase the possibility of potential targets and therefore, enhance 
the chances of SA-4-lBBL and SA-OX40L to act on one or more cell types. It is likely 
that CD8+ T cells are the common target for both the ligands as both the receptors are 
reported to be expressed on CD8+ T cells following TCR signaling and enhance CD8+ T 
cell response with the binding of agonistic mAbs, mostly via improved CD8+ T cell 
effector function and their survival (67, 117). Therefore, dual costimulation through SA-
4-1BBL and SA-OX40L could enhance effector function of CD8+ T cells. Consistence 
with this notion, we observed an improved effector CD8+ T cells response, as measured 
by IFN-y and IL-2 double cytokines, in the mice subjected to SA-4-lBBL and SA-
56 
OX40L combination therapy when compared to single agents. Most importantly, 
depletion of CD8+ T cells in the combination therapy almost completely abrogated the 
vaccine efficacy suggested the critical role these cell population play in the combination 
therapy. 
The effect of SA-OX40L on combination therapy, an alternative to its direct 
effect on CD8+ T cells, could also be due to its influence on promoting CD4+ T cells help. 
Although previous reports has shown the null effect of CD4+ T cell help on the efficacy 
of anti-4-1 BB and anti-OX40 mAbs combination therapy as depletion of CD4+ T cells 
did not abrogate the efficacy (118), we observed the completely opposite result which 
suggests the involvement of CD4+ T cell in vaccine efficacy. Physical depletion of CD4+ 
T cells in our model system significantly compromised the efficacy if SA-OX40L 
monotherapy as well as combination of SA-4-1BBL and SA-OX40L combination 
therapy, suggesting the influence of SA-OX40L on CD4+ T cells. This observation is in 
congruence with our initial functional assays where SA-OX40L shows preferential 
effects on CD4+ T cells. 
Finally, both 4-1BB and OX40 expression have been reported on Tregs cell and 
signaling via agonistic Abs and/or natural ligands to these receptors have been reported to 
abrogate the Treg-mediated immunosupression (81, 119). Inhibition of Treg-mediated 
suppression is one of the most critical phenomena required for therapeutic vaccine 
efficacy. Consistence with this notion, we also observed the lower Treg numbers in 
spleen of the mice subjected to combination therapy. Although the exact mechanistic 
basis of effect of SA-4-1 BBL and SA-OX40L on the reduced number of Tregs observed 
in our model is unknown, it is possible that SA-OX40L may preferentially induce 
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apoptosis in Treg cells as previously reported (120) or SA-4-1BBL may block the 
conversion of Teff cells into induced Tregs as supported by our unpublished data 
demonstrating that SA-4-1BBL blocks tumor- and TGF-~-induced conversion of Teff 
cells into induced Treg cells through IFN-y (Madireddi et aI., manuscript submitted). 
In conclusion, regardless of potential mechanisms, our data strongly supports the 
use of combination ofSA-4-1BBL and OX40L as the immunomodulatory components of 
therapeutic vaccines against cancers with significant clinical potential. 
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Hypothesis: Coordination between CD4+ and CD8+ T cells. SA-OX40L primarily targets 
CD4+ T cells while SA-4-1 BBL targets CD8+ T cells. SA-OX40L-mediated CD4+ T cells 
further become either effector cells or help SA-4-1BBL-mediated CD8+ T cells effector 
response for robust anti-tumor immunity. Additionally, both SA-OX40L and SA-4-1BBL 
together reverse the Treg-mediated suppression either directly or indirectly, provide 
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Construction and characterization of SA-OX40L protein. The extracellular domain of 
mouse OX40L was cloned C-terminal to core SA in the PMT/BiP/V5-HisA vector (A). 
After sub-cloning, right size of OX40L band (lane 2) was shown by gel electrophoresis 
(B). Binding of OX40L to OX40 receptor (C). Naive or ConA activated C57BLl6 
splenocytes were incubated with SA-OX40L (200 ngllxl06 cells) or equimolar amount 
of SA protein and binding of SA-OX40L on CD4+ (top panel) and CD8+ T cells (bottom 
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SA-OX40L induces CD4+ T cell proliferation but not CD8+ T cell in vitro. CD4+ T cell 
(A) and CD8+ T cell (B) proliferation. Flow purified CD4+ and CD8+ T cells were 
stimulated for 48h with suboptimal dose of anti-CD3 Ab with various doses of SA-
OX40L in the presence of irradiated syngeneic splenocytes. Cells were pulsed with eH]-
thymidine for the last 16 h of culture. Data are representative of minimum of three 
independent experiments. 
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Figure 13 
In vivo OT-I and OT-II cell proliferation in peripheral LNs. Two million OT-I and OT-II 
T cells (CD45.2l each were labeled with CFSE and injected (i.v.) into congenic 
C57BL/6.SJL (CD45.1 +) mice. Mice were vaccinated 24h later with either OVA (3 Ilg) 
alone or in combination with SA-OX40L (5 Ilg). Proliferation of both OT-II (top panel) 
and OT-I (bottom panel) was assessed using FACS caliber 3 days after vaccination by 
gaiting on CD4+CD45.2+ and CD8+CD45.2+ cells. Data are representative of minimum of 
three independent experiments. 
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Figure 14 
Combination of SA-4-1BBL and SA-OX40L completely eradicates the TC-l tumors. 
C57BLl6 mice were challenged with lx105 live TC-l cells in the right flank and 
vaccinated s.c. on day 6 post tumor challenge with either E7 alone (50 Jlg) or with SA-4-
IBBL (25 Jlg) or SA-OX40L (25 Jlg) or combination of both agents (25 Jlg + 25 Jlg). * P 
< 0.05 for combination therapy vs. all other groups. 
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Figure 15 
Vaccination with the SA-4-1BBL+SA-OX40L induces strong multi-functional cytokine 
and memory responses by CD8+ T cells, and reduces Treg percentage that correlates with 
vaccine efficacy. Long-term (> 90 days) surviving mice were boosted with the same 
indicated vaccine formulations used for primary vaccination. Lymph node cells were 
harvested 7 days later and assessed for E749-57 peptide-specific CD8+ T cells expressing 
intracellular IPN-y mono (A), IPN-yIL-2 double cytokines (B). Splenocytes from the 
same groups were phenotyped to test the percentage of effector memory 
CD44hiCD62LlowCD8+ T cells (C) and CD4+Poxp3+ cells (D). Data for each panel are 
representative of two independent experiments that include 3-4 mice per group. P values 
were as shown and calculated using one way ANOV A and Tukey HSD test (ns = not 
significant). 
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Figure 16 
Combination of SA-4-1BBL and SA-OX40L generates better OT-I and OT-II cell 
proliferation in vivo. Two million OT-I and OT-II T cells (CD45.2+) each were labeled 
with CFSE and injected (i.v.) into congenic C57BLl6.SJL (CD45.1 +) mice. Mice were 
vaccinated 24h later with either OVA (3 /lg) alone or in combination with SA-OX40L (5 
/lg) or SA-4-1BBL (5 /lg) or combination of both agents (5 /lg + 5 /lg). Proliferation of 
both OT-II (top panel) and OT-I (bottom panel) was assessed using FACS caliber 3 days 
after vaccination by gating on CD4+CD45.2+ and CD8+CD45.2+ cells. Data are 
representative of minimum of three independent experiments. This figure also contains 
partial data from figure 13. 
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Therapeutic efficacy of SA-OX40L+SA-4-1BBL combination and SA-OX40L mono 
therapies requires both CD8+ and CD4+ T cells. CD4+ and CD8+ T cells were depleted 
using Abs against CD8 and CD4 molecules, respectively, one day before vaccination 
with E7 TAA and the indicated vaccine formulations using the TC-l tumor model. ** P 
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Combination of SA-4-1BBL and SA-OX40L has robust therapeutic efficacy in 
eradicating 3-4 mm established TC-1 tumors. C57BLl6 mice were challenged with 1x105 
live TC-1 cells in the right flank. Once tumor size reaches 3-4 mm in size, mice were 
vaccinated s.c. with either E7 alone (50 Ilg) or with SA-4-1BBL (25 Ilg) or SA-OX40L 
(25 Ilg) or combination of both agents (25 Ilg + 25 Ilg) twice on day 5 and day 10, and 
followed for 100 days. ** P < 0.001 for combination therapy vs. all other groups. 
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CHAPTER 4 
SA-4-1BBL AND MPL COMBINATION AS AN ADJUVANT SYSTEM SHOWS 
ROBUST THERAPEUTIC EFFICACY BY INCREASING INTRATUMORAL 
CDS+ T EFFECTORlCD4+Foxp3+ T REGULATORY CELL RATIO 
Introduction 
Therapeutic vaccines are preferred alternatives to conventional treatments for 
cancer primarily because of their safety profile and generation of long-term 
immunological memory critical for the control of recurrences, which are the main cause 
of death from cancer. Therapeutic vaccines based on tumor associated antigens (TAAs) 
are particularly attractive because of their ease of production, scale-up, storage, and 
administration to a broad patient population. The efficacy of such vaccines, however, is 
curtailed by the weak antigenic nature of self T AAs due to both central and peripheral 
tolerogenic mechanisms (121, 122). These limitations can potentially be overcome by 
developing vaccine formulations including adjuvants that not only generate potent 
immune responses against T AAs with long-term immunological memory, but also 
overcome various immune evasion mechanisms. 
Recent advances in our understanding of the immune system, mechanistic basis of 
immune activation, response, and establishment of long-term immunological memory, 
and key molecules involved in regulating such responses have provided an unparalleled 
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opportunity to design adjuvants with known molecular actions and desired activities for 
the development of effective and safe therapeutic vaccines. Critical to the activation and 
maintenance of an immune response are the signals transduced by toll-like receptor 
(TLR) and costimulatory receptor pathways (123, 124). As such, agonistic ligands to 
receptors of these two pathways have significant potential as adjuvants for therapeutic 
vaccines. Consistent with this notion is the approval of TLR-4 agonist MPL, a nontoxic 
version of lipopolysaccharide, by FDA to be used as the adjuvant component of a 
preventive vaccine against HPV infection (125). However, the efficacy of MPL as the 
adjuvant component of therapeutic vaccines against cancer remains to be demonstrated. 
MPL primarily targets innate immunity, leading to the recruitment, activation, and 
maturation of antigen presenting cells (APCs), such as DCs that facilitate the generation 
of adaptive immune responses (126) (Fig. 19). 
Unlike TLR pathway, costimulation directly targets adaptive immunity and is 
critical for the generation of primary as well as memory T and B cell responses (124), 
which led us to recently propose costimulatory ligands as potential adjuvants of choice 
for the development of therapeutic cancer vaccines (111). In particular, we focused on 4-
1BBL as the costimulatory member of TNF family because of the critical role of this 
molecule in the generation and maintenance ofCD8+ T cell responses (127, 128) and the 
importance ofCD8+ T cells in eradication of tumors (129, 130). Inasmuch as 4-1BBL is 
a cell surface membranous protein and has no function in soluble form, we fused the 
extracellular functional domain of this molecule to a modified form of core streptavidin 
(SA) to generate a chimeric molecule (SA-4-1BBL) that exists as tetramers and 
oligomers owing to the structural features of SA (112). SA-4-1BBL has potent immune 
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· activity in soluble form and targets T effector (Teff) cells for activation, acquisition of 
effector functions, and establishment of long-term memory that translate into robust 
therapeutic efficacy in various preclinical models (111, 112, 131, 132). Most 
importantly, SA-4-1BBL also modulates regulatory immunity by reversmg tumor 
induced clonal anergy, rendering Teff cells resistant to suppression by 
CD4+CD2S+FoxP3+ T regulatory (Treg) cells (111), and inhibiting the conversion of Teff 
cells into Treg cells through the production of IFN-y (Madireddi et aI., manuscript 
submitted). These combined effects results into better therapeutic efficacy in cancer 
setting as compared with two TLR agonists, CpG and MPL (111). 
Given that MPL primarily targets APCs , such as DCs and macrophages, for the 
initiation of adaptive immunity (126) and 4-1 BBL targets CD8+ T cells for activation, 
acquisition of effector function, survival, and long-term memory (133-135), and the 
critical role of CD8+ T cells for tumor eradication (129, 130), we hypothesized that an 
adjuvant system composed of both of these molecules may have potent therapeutic 
efficacy as the component of TAA-based vaccine formulations against cancer (Fig. 20). 
Consistent with this notion, a single vaccination with both adjuvants and E7 T AA 
resulted in effective eradication of E7 expressing TC-I tumor in all mice. This effect was 
extendable to the 3LL pulmonary lung carcinoma model where survivin (SVN) was used 
as a bona fide self-T AA. The intratumoral CD8+ Teff/Treg cell ratio played a definitive 
role in the efficacy of the vaccine, which was confirmed by the depletion of CD8+ Teff 
and Treg cell populations. Taken together, these data demonstrate the utility combination 
of SA-4-IBBL and MPL together as a novel adjuvant system for the development of 
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therapeutic T AA-based subunit cancer vaccines which may have a significant clinical 
potential. 
Materials and Methods 
Mice and cell lines 
C57BLl6 and C57BLl6.SJL mice were bred in our barrier animal facility at the 
University of Louisville. All animals were cared for in accordance with institutional and 
NIH guidelines. TC-I and 3LL cell lines were purchased from ATCC (Manassas, VA) 
and maintained as published (111). 
Antibodies and other reagents 
Fluorochrome-conjugated anti-CD8-APC-Cy7, anti-CD62L-PE, anti-CD44-APC, 
anti-TNF-PE, anti-IFN-y-PE-Cy7, and anti-IL-2-PerCp-Cy5.5, and isotype controls were 
purchased from BD Bioscience, eBioscience, and BioLegend. MPL was purchased from 
InvivoGen (San Diego, CA). The HPVI6 RAHYNIVTF E7 peptide (E749-57), SA-4-
IBBL, E7 and mouse SVN proteins were reported previously (111). 
Tumor models and vaccination 
C57BLl6 mice were challenged subcutaneously (s.c.) with lxl05 live TC-I cells 
into the right flank. For therapy, mice were vaccinated s.c. on day 6 post-tumor challenge 
with various vaccine formulations containing E7 protein (50 Ilg) alone as control or with 
SA-4-1 BBL (25 Ilg), MPLA (25 Ilg), or the combination of both agents (25 Ilglagent). 
The doses ofE7, SA-4-IBBL, and MPL used in this study were based on our previously 
published studies (111). Mice were euthanized when tumor reached a size of 12 mm in 
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diameter, ulcerated, or mice showed signs of discomfort. CDS+ and CD4+ T cells were 
depleted using Abs against CDS (clone 53.6.72) and CD4 (clone GK 1.5) at 500 Jlg/mice 
via intra peritoneal injection one day before vaccination. 
For the pulmonary tumor model, 2x10s live 3LL cells were injected i.v. into the 
tail vein of mice. Mice were vaccinated s.c. either once on day 6 or twice on days 6 and 
12 post-tumor challenge with various vaccine formulations containing SVN protein (50 
Jlg) alone as control or with SA-4-1BBL (25 Jlg), MPL (25 Jlg), or the combination of 
both agents (25 Jlg/agent). Mice were euthanized 27 days post-tumor challenge for 
analysis of lung tumor burden as described (112, 136). 
Flow cytometry and confocal microscopy 
Spleens and/or tumor draining lymph nodes (TdLNs) were processed as described 
previously (111). For memory T cell typing, lymphocytes were stained with anti-CDS-
APC-Cy7, anti-CD62L-FITC, and anti-CD44-APC Abs. For intracellular cytokine 
staining, lymphocytes (lx106 cells/mL) were stimulated either with 10 Jlg/mL E749-S7 
peptide for 2 hrs followed by incubation with GolgiPlug (1 JlI/mL, BD PharMingen) 
overnight or with PMA (5 ng/ml, Sigma) and ionomycin (500 ng/ml, Sigma) for 2 hrs 
followed by incubation with GolgiPlug (1 JlI/ml) for an additional 4 hrs. Cells were first 
stained with anti-CD44-APC and anti-CDS-APC-Cy7, fixed with 4% paraformaldehyde, 
and then stained with anti-IFN-y-PE-Cy7, anti-IL-2-Percp-Cy5.5, anti-TNF-PE, or 
isotype controls followed by acquisition and analysis as previously reported (112). 
Intratumoral CDS+ T cells and CD4+Foxp3+ Treg cells were analyzed using confocal 
microscopy as described (112). 
Analysis of autoantibody to ssDNA 
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A ssDNA ELISA was perfonned to assess the presence of auto-Abs in treated 
mice as described (137). Briefly, ninety six titer plates coated with 1 !Jglwell of heat-
denatured calf thymus DNA (ssDNA, Sigma) were blocked with PBS containing 5% 
BSA + 0.5% Tween 20 + 0.1 % naive C57BLl6 serum. Serum dilutions were added to 
wells and incubated at 4°C overnight. Wells were washed 3 times, incubated with anti-
mouse IgG-HRP, and absorbance was measured at 450 nm. 
Results 
Combined use of SA-4-1BBL and MPL as the adjuvant component of E7 TAA-
based vaccine has robust efficacy in eradicating established TC-l tumors 
We recently demonstrated that a single vaccination with SA-4-1BBL and E7 
protein was effective in eradicating E7 expressing established TC-l tumors in > 70% of 
mice (112). Although impressive, we sought to test whether the therapeutic efficacy of 
this vaccine can further be improved by modifying the fonnulation to include MPL as the 
second adjuvant with primary effect on the innate immunity (126, 138). A single s.c. 
vaccination with E7 protein mixed with SA-4-1BBL and MPL resulted in the eradication 
of established TC-l tumors in all mice, which remained tumor-free over an observation 
period of 90 days (Fig. 2IA). In contrast, monotherapy with SA-4-1BBL and MPL 
resulted in eradication of tumor in only 80% and 50% of mice, respectively. Mice that 
expired from tumor in the single agent groups, however, had slow kinetics of tumor 
progression as compared with both PBS and E7 protein control groups where all mice 
expired from the tumor burden within 50 days (Fig. 21B). Taken together, these data 
demonstrate that SA-4-1BBLlMPL as an adjuvant system is effective in eradicating the 
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established TC-l tumors with better therapeutic efficacy than the individual agents, and 
that SA-4-1BBL has better efficacy than MPL. 
The therapeutic efficacy of the vaccine is associated with robust effects of SA-4-
IBBL and MPL on the generation of peripheral CDS+ T cell responses 
CD8+ T cell effector and memory responses are critical to the elimination of 
primary tumor and control of recurrences, respectively, in various tumor settings, 
including the TC-l model (111, 129-131). We, therefore, assessed the CD8+ T cell 
effector and long-term memory responses elicited by various vaccine formulations. Mice 
that had eradicated the tumor in response to various vaccine formulations were boosted 
s.c. with the same formulations and then euthanized one week later to test the 
intracellular cytokine response of CD8+ T cells to the dominant E749-57 epitope (129). 
Consistent with the therapeutic efficacy, vaccination with E7 protein and SA-4-
IBBLlMPL generated a better antigen-specific cytokine response than single adjuvant 
therapy as assessed by CD8+ T cell expressing IL-2, IFN-y, and TNF-a triple cytokines 
(Fig. 22A-C). Consistent with the therapeutic responses, mice vaccinated with SA-4-
IBBL formulation generated significantly (P < 0.05) better IFN-y response than the MPL 
formulation (Fig. 22A). We also observed E7 TAA-specific TC-l killing (Fig. 23A) 
responses in mice vaccinated with both adjuvants as compared with single adjuvants. 
Consistent with the therapeutic efficacy, SA-4-1BBL as monotherapy generated better 
killing responses than E7 antigen alone, whereas MPL failed to do so. Importantly, 
vaccine formulation with the SA-4-1BBLlMPL also generated the most effective CD8+ T 
cell memory recall responses as compared to those including SA-4-1BBL and MPL as 
single agents (Fig. 23B). Collectively, these data demonstrate that SA-4-1BBL and MPL 
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adjuvants work together to generate potent CD8+ T cell effector and memory responses 
that correlate with the therapeutic efficacy of the vaccine against the TC-1 tumor. 
Vaccination with the SA-4-1BBLIMPL adjuvant system results in a favorable 
intratumoral CDS+ Teff/Treg cell ratio 
Elevated levels of intratumoral CD4+Foxp3+ Treg cells along with a decline in 
CD8+ Teff cells is associated with a clinically unfavorable prognosis of cancer patients 
(139, 140) and depletion of Treg cells results in better immune efficacy of therapeutic 
vaccines (141, 142). Therefore, we evaluated the effect of SA-4-1BBLlMPL adjuvant 
system on the status of intratumoral Treg and Teff cells. Mice bearing ~3-4 mm TC-1 
tumor were vaccinated s.c. with various vaccine formulations. One week post-
vaccination, tumors were harvested and analyzed for the presence of intratumoral CD8+ T 
cells and CD4+FoxP3+ Treg cells using confocal microscopy. There was a significant 
reduction in the number of intratumoral Treg cells in mice vaccinated with either SA-4-
1BBL as a single adjuvant or in combination with MPL when compared with PBS 
controls or E7 protein alone. (Fig. 24A top panel and B). Interestingly, vaccine 
formulation containing MPL as a single adjuvant did not have detectable effect on the 
number of intratumoral Treg cells as compared with PBS control, and indeed performed 
worse than E7 protein alone that appreciably, but not statistically significant, reduced the 
intratumoral number of Treg cells. 
We next tested if a decrease in the number of Treg cells caused by SA-4-
1BBLlMPL or SA-4-1BBL as monotherapy inversely correlates with the number of 
intratumoral CD8+ T cells, a hallmark of successful immunotherapeutic approach against 
cancer (143). Vaccination with SA-4-1BBLlMPL had the most pronounced effect on the 
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number of intra tumoral CDS+ T cells infiltration followed by SA-4-1BBL, whereas MPL 
had a moderate effect that was similar to the E7 protein alone (Fig. 24 A bottom panel 
and C). This increased intratumoral CDS+ T cells by SA-4-1BBLIMPL resulted into the 
most favorable intratumoral TeffiTreg cell ratio followed by SA-4-1BBL as monotherapy 
(Fig. 24D). In marked contrast, MPL as a single adjuvant had no effect on the 
intratumoral Teff/Treg cell ratio as compared with both PBS and E7 protein controls. 
Taken together, these findings demonstrate that SA-4-1BBL and MPL work in synergy to 
increase the intratumoral TeffiTreg cell ratio that correlates with the potent efficacy of 
this adjuvant system in eliminating established tumors. 
CD8+ T cells are critical to the therapeutic efficacy of SA-4-1BBLIMPL adjuvant 
system while Treg cells are detrimental to the efficacy of MPL monotherapy 
To test if a high CDS+ Teff/Treg cell ratio can serve as a predictor of vaccine 
therapeutic efficacy, we used Abs against CDS and CD4 molecules to deplete CDS+ Teff 
and Treg cells, respectively. Mice with established TC-l tumors were treated with 
depleting Abs one day before vaccination with E7 protein admixed with SA-4-
IBBLlMPL or MPL as monotherapy. As shown in Figure 25, depletion of CDS+ T cells 
completely abrogated the therapeutic efficacy of SA-4-1BBLlMPL adjuvant system, 
while depletion of CD4+ T cells, including Treg cells, improved the therapeutic efficacy 
of MPL from 50 to 100%. Taken together, these data provide direct evidence for the 
opposing roles of CDS+ T and Treg cells in vaccine efficacy and point to the importance 
of Teff/Treg cell ratio as a predictor of vaccine efficacy/failure. 
Vaccination with SA-4-1BBLIMPL adjuvant system and SVN eradicates established 
3LL pulmonary metastatic tumors 
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The robust efficacy of vaccination with xenogeneic E7 T AA in combination with 
SA-4-1BBLlMPL in eliminating TC-l tumors in all mice led us to test if this efficacy is 
translatable to SVN as a weak and potentially tolerant self-TAA using the 3LL 
pulmonary metastasis model. Mice were challenged i.v. with a lethal dose of live 3LL 
cells followed by s.c. vaccination on day 6 with various formulations containing SVN 
recombinant protein and SA-4-1BBL and/or MPL as adjuvants. As shown in Fig. 26A, 
vaccine formulation containing both adjuvants had the most therapeutic efficacy over 
single adjuvants in controlling tumor growth as demonstrated by both lung weight and 
presence of tumor nodules. Similar to the TC-l model, vaccine formulation containing 
SA-4-1BBL had better efficacy in controlling tumor growth than MPLA, which had 
statistically significant (P < 0.05) effect in controlling tumor growth over PBS and SVN 
alone controls. The therapeutic efficacy of SA-4-1BBLIMPL and SA-4-1BBL, but not 
MPL, as monotherapy correlated with significantly (P < 0.05) higher number of CD8+ T 
cells expressing IFN-y+ as compared with PBS and SVN alone controls (Fig. 26B). 
Although lungs of SA-4-1BBLlMPL vaccinated mice had similar weights as 
compared with lungs of naive mice, some of the lungs had microscopically detectable 
tumor nodules. We therefore, tested the efficacy of a booster injection 7 days after the 
first vaccination. As shown in Figure 27, boosting with SA-4-1BBLIMPL resulted in 
complete eradication of lung tumor in all mice. Booster vaccination with single adjuvants 
was also effective in eradicating and/or controlling tumor burden that reached statistical 
significance (P <: 0.05) as compared with PBS and SVN alone controls. Collectively, 
these findings further confirm the utility of SA-4-1BBLIMPL as a powerful adjuvant 
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system to elicit potent immune responses to a self-T AA that translates into effective 
immunotherapy in a stringent pulmonary preclinical metastasis model. 
Therapeutic efficacy of the SA-4-1BBLIMPL adjuvant system is achieved in the 
absence of detectable clinical toxicity and autoimmunity 
Autoimmunity is a potential setback to effective self-T AA-based therapeutic 
vaccine formulations using potent adjuvants to induce immune responses to such antigens 
(144). Given the potent therapeutic activity of the adjuvant system used in this study, we 
tested serum from mice with successful immunotherapy for both the TC-l as well as 3LL 
models for the presence of Abs against ssDNA as a sign of systemic autoimmunity. 
There was lack of significant amount of auto-Abs to ssDNA in all the groups tested, 
whereas the serum from mice with full blown lupus had high levels of such Abs (Fig. 28). 
Importantly, we did not detect signs of acute toxicity in vaccinated mice based on weight 
loss, unexpected mortality, gross anatomy, and macroscopic analysis of body organs, 
demonstrating the safety profile of this adjuvant system. 
Discussion 
In the present study, we tested if the costimulatory ligand SA-4-1BBL and TLR-4 
agonist MPL with distinct mechanisms of action can serve as a novel adjuvant system for 
the development of therapeutic TAA-based subunit cancer vaccines. MPL collaborated 
with SA-4-1BBL as the adjuvant component ofHPV E7 TAA-based vaccine to generate 
robust primary CD8+ T cell effector and long-term memory responses that translated into 
improved therapeutic efficacy in the TC-l cervical cancer mouse model. The therapeutic 
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efficacy of the adjuvant system was totally dependent on CD8+ T cells and associated 
with a favorable intratumoral CD8+ TefflCD4+Foxp3+ Treg cell ratio. Importantly, the 
therapeutic efficacy of the adjuvant system was not limited to the xenogeneic E7 T AA, 
since a vaccine formulation containing SVN as a bona fide self-TAA was equally 
effective in eradicating/controlling tumors in the 3LL metastatic pulmonary cancer 
model. 
The choice ofSA-4-1BBL and MPL as the adjuvant system is due to their distinct 
mechanisms of action and targeting different immune cells for activation. MPL primarily 
targets innate immunity by interacting with the constitutively expressed TLR-4 on DCs 
and macrophages, leading to the production of various proinflammatory cytokines and 
upregulation of various costimulatory and MHC molecules that altogether regulate 
adaptive immune responses (126). SA-4-1BBL, on the other hand, interacts with the 
inducibly expressed 4-1 BB receptor on both CD4+ and CD8+ T cells, leading to their 
survival, expansion, acquisition of effector function, and long-term immune memory 
(133-135). Importantly, 4-1BB signaling appears to have the most effect on CD8+ T 
cells, which are critical to the eradication of tumors as demonstrated in various preclinical 
settings, including the TC-l model (111, 129-131). Therefore, MPL in the adjuvant 
system is expected to work with SA-4-1BBL for the activation of CD8+ T cells through 
the activation of DCs and antigen cross-presentation (145), resulting in the upregulation 
of 4-1 BB receptor on the surface of CD8+ T cells that in turn become the direct target of 
SA-4-1BBL. This scheme is supported by our current findings that MPL collaborates 
with SA-4-1BBL in generating robust CD8+ T cells primary and long-term memory 
responses that translate into effective therapy in two different established tumor models, 
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TC-l cervical and 3LL pulmonary carcinoma, with two different antigens, HPV E7 
xenogeneic and SVN bona fide self-T AA antigens. Consistent with this notion, depletion 
ofCD8+ T cells one day before vaccination completely abrogated the efficacy of the SA-
4-IBBLlMPL adjuvant system in eradicating TC-l tumors. In addition to its direct effect 
on CD8+ T cells, SA-4-IBBL may also augment the effect ofMPL on DCs by improving 
their antigen uptake and cross-presentation. This notion is supported by observations that 
a subpopulation of DCs constitutively express 4-IBB receptor (146, 147), and 
vaccination with SA-4-IBBL enhances their antigen uptake and cross-presentation (111, 
112). 
CD4+CD25+FoxP3+ Treg cells playa critical role in immune evasion mechanisms 
employed by acute (148) as well as chronic infections (149, 150) and cancer (122, 141, 
151), and as such serve as an important barrier for the efficacy of vaccines. Therefore, 
vaccine formulations that specifically control the number and/or function of Treg cells 
while enhancing the number of Teff cells may have desired therapeutic efficacy in 
settings of cancer and chronic infections. Consistent with this notion are studies 
demonstrating that the physical depletion of Treg cells or modulation of their regulatory 
function using Abs to various cell surface markers have protective and therapeutic effects 
against various tumors in preclinical models (151-155). Importantly, a recent study using 
mice transgenically expressing the diphtheria toxin receptor only in Treg cells 
demonstrated that specific and conditional depletion of these cells protected mice from 
carcinogenesis induced spontaneous tumors via innate immunity and eradicated 
established tumor via CD8+ T cell- and IFN-y-dependent responses (154). Consistent 
with preclinical studies, Treg cells were shown to accumulate in various progressing 
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cancers m patients and a high intratumoral Teff/Treg cells ratio is considered the 
hallmark of a favorable prognosis (139-141). Important in this context, we found a robust 
increase in the ratio of intratumoral CD8+ TeffiTreg cells in response to vaccination with 
the SA-4-1BBLIMPL adjuvant system. Vaccination with SA-4-1BBL as monotherapy 
also significantly improved the intratumoral CD8+ TeffiTreg cell ratio, which is 
consistent with our recently published data (112). Surprisingly, MPL as monotherapy 
was not only inefficient in significantly increasing the frequency of intratumoral CD8+ T 
cell infiltration, but also failed to decrease the intratumoral number of Treg cells, 
resulting in an unfavorable CD8+ Teff/Treg cell ratio. The Treg cells played a detrimental 
role in the efficacy of MPL-based vaccine since their depletion one day before 
vaccination resulted in eradication of all tumors (Fig. 25). This finding, to our knowledge 
first, demonstrating that MPL efficacy is compromised by Treg cells is significant and 
provides an important mechanistic insight in improving the efficacy of this FDA 
approved adjuvant for the development of therapeutic cancer vaccines. 
Although the primary targets of MPL are cells of innate immunity, a series of 
recent studies have demonstrated that this adjuvant may also directly targets cells of 
adaptive immunity. The expression of TLR-4 has been shown on CD4+ T effector and 
Treg cells (156, 157). Importantly, stimulation via this receptor on CD4+ Teff cells was 
shown to inhibit ERKII2 signaling pathway, resulting in the inhibition oftheir function in 
an experimental colitis model (157). In marked contrast, stimulation of Treg cells with 
the TLR-4 agonist lipopolysaccharide resulted in their survival, expansion, and improved 
regulatory function in vivo (156), which may account for the unfavorable intratumoral 
CD8+ TeffiTreg cell ratio seen in the MPL monotherapy group. Although the exact 
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mechanistic basis of the synergistic effect of SA-4-1BBL and MPL on the intratumoral 
CD8+ T/Treg cell ratio observed in our model is unknown, i) SA-4-1BBL may 
preferentially induce apoptosis in Treg cells as reported for the agonists of OX-40 
pathway (158), another close member ofTNFR costimulatory family, and/or ii) block the 
tumor-mediated conversion of Teff cells into induced Treg cells, while iii) both agents 
increasing the intratumoral frequency of CD8+ Teff cells, thereby favorably influencing 
the CD8+ Teff/Treg cell ratio. This notion is supported by our unpublished data 
demonstrating that SA-4-1BBL blocks tumor- and TGF-p-induced conversion of Teff 
cells into induced Treg cells through IFN-y (Madireddi et aI., manuscript submitted). The 
increased expression of IFN-y in response to SA-4-1 BBLlMPL adjuvant system in the 
present study is further consistent with this notion. Importantly, although we observed 
enhanced E7 TAA-specific frequency of CD8+ T cells expressing IFN-y in the periphery 
of mice vaccinated with MPL as monotherapy, this effect did not result in increased 
number of CD8+ T cells in the tumor, suggesting that these cells may not be trafficking 
into the tumor. In contrast, vaccination with SA-4-1BBLlMPL adjuvant system resulted 
in significantly higher numbers of CD8+ Teff cells both in the periphery and within the 
tumor, suggesting that both adjuvants in combination may affect the trafficking/entry of 
CD8+ Teff into the tumor and/or improve their survival. 
Importantly, the therapeutic activity of SA-4-1BBLlMPL adjuvant system was 
achieved in the absence of detectable acute toxicity and chronic autoimmunity. The lack 
of acute toxicity is consistent with our previously published studies demonstrating that 
treatment of mice with 4-fold higher SA-4-1BBL over the therapeutic dose used in this 
study did not result in detectable toxicity as assessed by systemic cytokine response, non-
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specific lymphoproliferation, altered lymphocyte trafficking, generalized lymphomegaly 
and splenomegaly, and hepatitis, all of which were observed with similar doses of an 
agonistic Ab to 4-1BB receptor (132). The safety ofMPL has already been demonstrated 
both in preclinical and clinical settings (125, 126, 138). 
In conclusion, the studies presented in this communication demonstrate the robust 
efficacy of the SA-4-1BBLlMPL adjuvant system in inducing potent CD8+ Teffprimary 
and long-term memory responses against T AAs and a favorable intratumoral CD8+ 
TefflTreg cell ratio that translate into potent therapeutic efficacy in two different tumor 
models. Importantly, the therapeutic efficacy of the vaccines was observed in the 
absence of detectable acute toxicity or chronic autoimmunity. The better immune and 
therapeutic efficacy of SA-4-1 BBLlMPL over MPL as monotherapy combined with MPL 
being a clinically approved adjuvant (125) emphasizes the importance of further 
developing this adjuvant system and assessing its efficacy as component of subunit 









) Adaptive Immunity 
Targeting innate and adaptive immunity. Innate immune cells such as dendritic cell 
engulf pathogens and present pathogen-derived peptide antigens to naIve T cells. 
Additionally, TLRs recognize pathogen-derived components and induce expression of 
costimulatory molecules and inflammatory cytokines. On the other hand, costimulatory 
SA-4-1BBL also induce the dendritic cells activation and antigen cross- presentation. 
Phagocytosis-mediated antigen presentation, TLR-mediated expression of co-stimulatory 
molecules and inflammatory cytokines together with SA-4-1 BBL-mediated dendritic cell 
activation and cross-presentation instruct development of antigen-specific adaptive 
immunity, especially Thl cells. 
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activation and cross-presentation instruct development of antigen-specific adaptive 












Hypothesis: Synergy between innate and adaptive immunity. MPL is recognized by TLR-
4 expressed on dendritic cells and induce expression of costimulatory molecule 4-1 BB 
and inflammatory cytokines such as IL-12, IL-6, and TNF. On the other hand, 
costimulatory SA-4-1 BBL also activates the dendritic cells by inducing CD80, CD86, 
and CD40 expression and enhances antigen cross- presentation. MPL-mediated 
expression of 4-1BB and inflammatory cytokines together with SA-4-1BBL-mediated 
dendritic cell activation and cross-presentation instruct development of antigen-specific 
adaptive immunity synergistically to target tumor cells. Additionally, combination of SA-
4-1BBL and MPL also targets the Tregs and MDSCs to avert their suppression on 
effector cells. Take together, combination therapy targets all arm of the immune system 
including innate, adaptive and regulatory. 
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Figure 21 
A single vaccination with the SA-4-1BBLIMPL adjuvant system results in the eradication 
of established TC-l tumor in all mice. A, C57BLl6 mice were challenged s.c. with lxl05 
live TC-l cells and left unvaccinated (PBS) or vaccinated once s.c. on day 6 post-tumor 
challenge with E7 (50 Ilg) mixed with control SA protein (10 Ilg) or SA-4-1BBL (25 Ilg), 
MPL (25 Ilg), or the combination of both agents (25 Ilg/agent). The log-rank test and 
Kaplan-Meier method were used for analyses. * P < 0.05 as compared to all the other 
groups, but SA-4-1BBL that was not significant (ns). B, Data from (A) are presented for 
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E7+MPL E7+SA-4-1BBL E7+MPL+SA-4-1BBL 
Vaccination with the SA-4-IBBLIMPL adjuvant system induces strong multi-functional 
cytokine responses by CD8+ T cells that correlate with vaccine efficacy. Long-term (> 90 
days) surviving mice were boosted with the same indicated vaccine formulations used for 
primary vaccination. Lymph node cells were harvested 7 days later and assessed for 
E749-57 peptide-specific' CD8+ T cells expressing intracellular IFN-y mono (A), IFN-
yTNF-a double (B), and IFN-yTNF-aIL-2 triple (C) cytokines. Data for each panel are 
representative of two independent experiments that include 3-4 mice per group. P values 
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E7+MPL E7+SA-4-1BBL E7+MPL+SA-4-1BBL 
Vaccination with the SA-4-1BBLlMPL adjuvant system induces cytolytic and memory 
responses that correlate with vaccine efficacy. Long-tenn (> 90 days) surviving mice 
were boosted with the same indicated vaccine fonnulations used for primary vaccination. 
A, Splenocytes were stimulated with E749-57 peptide and IL-2 for 5 days and used as 
effectors against TC-l tumors. 3LL tumor cells were used as irrelevant targets B, 
Splenocytes from the same groups were phenotyped to test the percentage of effector 
memory CD44hiCD62LlowCD8+ T cells. Data for each panel are representative of two 
independent experiments that include 3-4 mice per group. P values were as shown and 
calculated using one way ANOVA and Tukey HSD test (ns = not significant). 
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Figure 24 
Vaccination with the SA-4-1BBLlMPL adjuvant system results in an increase in the 
intratumoral Teff/Treg cells ratio. Mice bearing TC-l tumor (~3-4 mm in diameter; n = 4 
per group) were vaccinated s.c. with E7 protein (50 J.1g) alone or with SA-4-1BBL (25 
J.1g), MPL (25 J.1g), or a combination of both agents (25 J.1g/agent). One week post-
vaccination, tumors were harvested and stained for intratumoral CDS+ T cells and 
CD4+Foxp3+ Treg cells followed by analysis using confocal microscopy. A, Confocal 
pictures of tumor sections showing CD4+Foxp3+ Treg cells (top panel) stained with anti-
CD4 Ab (red), anti-Foxp3 Ab (green), and Hoechst (blue), and CDS+ T cells (bottom 
panel) stained with anti-CDS Ab (red) and Hoechst (blue). Quantitative analysis of 
intratumoral CD4+Foxp3+ Treg cells (B), CDS+ T cells (C), and CDS+ TeffiTreg cell ratio 
(D). P values were as shown and calculated using one way ANOV A and Tukey HSD test 
(ns = not significant). 
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Figure 25 
Therapeutic efficacy of SA-4-1BBLlMPL adjuvant system requires CDS+ T cells while 
Treg cells compromise the efficacy of MPL monotherapy. CDS+ T cells and Treg cells 
were depleted using Abs against CDS and CD4 molecules, respectively, one day before 
vaccination with E7 T AA and the indicated adjuvant system using the TC-1 established 
tumor model. Data for PBS, E7+MPL, and E7+MPL+SA-4-1BBL groups were taken 
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Vaccination with the SA-4-1BBLlMPL adjuvant system generates potent therapeutic 
response in the 3LL lung metastasis model. Mice (n = 4-5/group) were challenged with 
2xl05 live 3LL cells by i.v. tail injection and vaccinated once s.c. on day 6 or twice on 
days 6 and 13 post-tumor challenge with SVN (50 Ilg) alone or antigen with SA-4-1BBL 
(25 Ilg), MPL (25 Ilg), or a combination of both agents (25 Ilglagent). A, Lungs were 
harvested 27 days post tumor challenge and assessed for tumor growth by weight and 
macroscopic presence of tumor nodules. B, Intracellular IFN-y response of CD8+ T cells 
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Additional vaccination with SA-4-1BBLIMPL adjuvant system almost completely 
eradicates the lung tumors. Lungs harvested from mice with two vaccinations are 
assessed as in (Fig. 14). P values were as shown and calculated using one-way ANOVA 
and Post Hoc LSD test (ns = not significant). 
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Figure 28 
Vaccination with the SA-4-1BBLlMPL adjuvant system does not promote autoimmunity. 
Sera were harvested from mice challenged with 3LL tumor cells shown in Fig. 26 and 
TC-l tumor cells in Fig. 21 A at the experimental end points and tested for the presence of 
autoantibody against ssDNA in ELISA. Serum pooled from a minimum of 3 naive and 3 
lupus mice were used as negative and positive controls, respectively. 
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CHAPTER 5 
CONCLUSIONS AND FUTURE PROSPECTIVES 
The immune system has a potential to specifically recognize and eliminate cancer 
cells without damaging normal healthy cells. As a result, therapeutic vaccination strategy 
has been a promising approach to harness the immune system against disseminated 
cancers. Among all, therapeutic cancer vaccines based on T AA presents an attractive 
choice due to their safety profile, ease of production, storage, transportation, 
administration to a broad patient population and most importantly establishment and/or 
maintenance of long-term immunological memory critical for the control of recurrences. 
However, the effectiveness of these vaccines will not only depend on their ability to 
promote robust immune response but also overcome various immune evasion 
mechanisms employed by progressing tumors. In this context, utilization of 
immunomodulators which modulate the innate, adaptive, and regulatory immunity for 
controlling the tumor progression will have better chance to succeed in clinic. Therefore, 
utilization of SA-4-IBBL as a choice of adjuvant was a rational attempt due to its 
pleiotropic effects on cells of innate, adaptive and regulatory immunity. In this project, 
we first hypothesized that costimulatory SA-4-IBBL can be exploited to be a component 
of successful therapeutic cancer vaccines in preclinical tumor models. We show that a 
single vaccination of soluble form of SA-4-IBBL with SVN is able to eradicate SVN-
expressing 3LL carcinoma in over 70% of mice without a sign of autoimmunity. 
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During the last several years, there has been better understanding about the 
suppressive mechanisms employed by progressing tumors that hampers the induction of 
robust immune responses. These understandings have revealed new insight into how 
suppressive cells such as Tregs and MDSCs could potentially be cleared or inhibited for 
better therapeutic efficacy. In this regard, combination of diverse agents (combination 
therapy) has shown a great potential against cancers due to their distinct mechanism of 
actions. For example, combination of chemotherapeutic agents have been shown to 
enhance cross-presentation leading to the augmentation of tumor-specific adaptive 
immune response. Similarly, combination of adjuvants such a as TLRs that target 
primarily innate immune response and stimulate Thl cytokines promote the efficiency of 
T cell priming. Although an enormous efforts has been made in understanding the role of 
combination therapy on tumor-immune interaction at both molecular and cellular levels, 
clinical transitions is still in its infancy. But the development of effective cancer vaccines 
received a great boost after a vast understanding of DC as well as effector/Treg biology 
which clearly laid the ground for the development of improved clinical protocols. It is 
now believed that rather than quantity, it is important to generate high quality and high 
avidity polyclonal and poly-functional effector CD8+ T cells which are able to reject 
tumors and long-lasting memory CD8+ T cells which are able to control recurrences. 
Therefore, in this study, we attempted to utilize several combinatorial strategies that are 
usually presented in discordant manner which set a platform for the development of 
future therapeutic cancer vaccines. We here show that combination ofSA-OX40L+SA-4-
IBBL and SA-4-1BBL+MPL based therapeutic vaccine effectively enhanced poly-
functional CD8+ T effector cells. Combination SA-4-1BBL+MPL was also able to 
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increase intratumoral CD8+ T effector/CD4+FoxP3+ T regulatory cell ratio. These all 
mechanistic outcomes eventually translated into a complete eradication of tumors in both 
TC-I and 3 LL tumor models. In last, this study also supports that future 
immunotherapeutic cancer research should address multifunctional nature of the disease 
using combination protocols. 
The promising results from this overall Ph.D. study may provide a new avenue for 
cancer vaccine immunotherapy. However, despite the exciting improvements in the 
efficacy of various vaccine formulations studied in this study including tumor-free 
survival, there is still much to determine about the immunological mechanisms by which 
these results can be translated into the clinics. Additionally, it is also imperative to 
improve our understanding of CTL activation, NK activation, decreased Treg numbers 
and functionality, and impact of tumor escape. 
In overall, these studies provide proof-of-principle data of the utilization SA-4-
IBBL alone or in combination with other immunomodulators (adjuvant systems) which 
set a platform for clinical studies. Based on these studies, it is required to test the efficacy 
of these adjuvant systems in more clinically relevant spontaneous tumor models with the 
standard clinical practice. Eventually, testing these adjuvant systems in clinical trials will 
assess the therapeutic potential of these adjuvant systems, and if proven efficacious in 
therapeutic regimen, these adjuvant systems can be utilized against broad cancer types 
with well defined T AAs. 
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